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ABSTRACT 
Research evidence supports the use of marijuana for the purpose of relieving medical symptoms and, therefore, 
the Canadian courts granted Canadians legal access to marijuana for medical purposes. More than 40,000 
Canadians are currently approved to use medical marijuana, with an additional 400,000 Canadians reporting use 
of marijuana for medical purposes. During the study period, Marihuana for Medical Purposes Regulations 
(MMPR) was the medical marijuana regulation in effect in Canada, which allowed patients with a medical 
document from a physician to purchase dried marijuana from a Health Canada licensed producer. Medical 
marijuana regulations infer how medical marijuana is to be accessed and used. The mode of delivery—whether 
marijuana is smoked, vapourized, or consumed—may have important implications for potential therapeutic 
efficacy, as well as health risks. Anecdotal evidence suggests that the use of alternative and innovative modes of 
delivery is on the rise; however, there is very little evidence on current patterns of use among Canadian medical 
marijuana users, particularly with respect to modes of delivery. The primary objective of the current research 
was to examine patterns of use among Canadians using marijuana for medical purposes. The study had five 
specific aims: 1) To estimate the prevalence of different modes of delivery, 2) To examine perceptions and 
importance of various factors for different modes of delivery, 3) To estimate the prevalence of different forms of 
marijuana, 4) To examine the reasons for using different forms of marijuana, and 5) To assess prevalence and 
perceptions of different sources for obtaining medical marijuana. An overall sample of 364 approved adult 
Canadian medical marijuana users completed an online cross-sectional survey between April 29 and June 8, 
2015. Participants were recruited through a convenience sample from Health Canada licensed producers. Nine 
Health Canada licensed producers from across Canada helped recruit participants mainly through email. The 
results showed that using a vapourizer was the most popular mode of delivery currently used (53%), even more 
so than smoking a joint (47%), indicating a possible increase in the use of vapourizers among approved medical 
users since the introduction of the MMPR. The main reason participants reported using a vapourizer was to 
reduce negative health consequences associated with smoking. Furthermore, current use of a vapourizer was 
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associated with fewer respiratory symptoms (OR=1.28, 95%CI: 1.05-1.56, p=0.01) supporting that the use of 
vapourizers may be less harmful than smoking. Overall, 75% of participants reported using dried herb due to it’s 
easy accessibility, as it was the only legal form of marijuana available for purchase from licensed producers. It is 
important to note that accessibility of the forms of marijuana may change due to the recent revision to the 
MMPR allowing alternative forms of marijuana, in addition to dried herb, to be sold by licensed producers. 
Licensed producers, as the only legal source for obtaining medical marijuana at the time, was preferred by most 
approved users (44%). However, the city of Vancouver did not agree that licensed producers were a sufficient 
source for obtaining medical marijuana, thus, against federal medical marijuana law, decided to allow 
dispensaries and clubs to sell marijuana. Monitoring implications of such current and future changes to medical 
marijuana regulations may be beneficial to policymakers. Specifically, continuing to monitor and track medical 
marijuana use trends in terms of modes, forms, and sources in light of the present data. Overall, the current 
study addressed an important evidence gap on patterns of medical marijuana use in Canada following the 
introduction of the MMPR as it is critical to understand the population of medical users in order to inform 
marijuana policy.  
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1.0 INTRODUCTION 
1.1 Marijuana 
Marijuana is a mixture of dried and shredded leaves, stems, seeds, and flowers of Cannabis Sativa or 
Indica also known as the hemp plant1. Marijuana has been used throughout history and all around the 
world recreationally, as well as for medicinal purposes2. However, in recent years there has been an 
increase in attention regarding the use of marijuana as a therapeutic medicine, as well as a growing 
push for the possible legalization of its use.  
 
1.2 Physiological effects  
Approximately 70 compounds have been identified in the marijuana plant, which are called 
cannabinoids. Delta-9-tetrahydrocannabinol (THC) is the main active cannabinoid in marijuana and is 
responsible for the psychoactive and some medicinal effects3,4. Other cannabinoids include cannabidiol 
(CBD), which may be accountable for some therapeutic benefits, and cannabinol (CBN), which has 
approximately 10% of the activity of THC3,5. Cannabinoids bind to cannabinoid receptors that are 
present in the peripheral cells and neurons of the central nervous system6. Cannabinoids may bind to 
and act through two receptor types: cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2)4. 
CB1 receptors are primarily found in the central nervous system, whereas CB2 receptors are thought to 
be primarily distributed in the peripheral system6. Cannabinoids affect neurotransmitter release 
through binding to CB1 and CB2 receptors, which may result in multiple behavioural and mood 
changes, as well as euphoria6. Receptor distribution may vary from person to person; therefore, 
individual variation in the effects resulting from marijuana use can occur as well as expected effects of 
marijuana can influence individuals’ experiences6. 
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The psychoactive effects associated with marijuana use include euphoria, relaxation, time-distortion, 
intensified sensory experiences, loss of inhibitions, and at moderate and higher doses, decreased 
short-term memory and motor skills3,7. These psychoactive effects, primarily caused by THC, generally 
last several hours and may be accompanied by hunger cravings2. THC is lipid soluble and inactive THC 
metabolites can be detected in urine up to one month after use in the case of regular users2.  
 
1.3 Therapeutic Benefits 
The effectiveness of marijuana as a medicine is complicated by the diverse conditions, symptoms, 
marijuana strains, modes of delivery, and genetics. To date, biological and clinical research evidence 
provides strong support for the therapeutic benefits of marijuana for the following: analgesic for pain, 
antispasm for multiple sclerosis, anticonvulsive for epilepsy, nausea suppressant for chemotherapy, 
and appetite stimulant for wasting in HIV/AIDS patients3,8,9. Additionally, marijuana can reduce 
intraocular pressure for the treatment of glaucoma, however, other medications are recognized as 
more effective at this time8,9. There is promising data demonstrating anti-inflammatory effects of 
marijuana in treating rheumatoid arthritis and inflammatory diseases of the gastrointestinal tract8. On 
the other hand, the evidence is less clear regarding marijuana’s therapeutic effect for psychiatric 
disorders, including anxiety, depression, sleep disorders, and post-traumatic stress disorder3.  
 
There seems to be a high prevalence of medical marijuana users who use their medical marijuana to 
treat multiple conditions10. For example, one study found that users treated an average of more than 
six conditions with marijuana11-13. The most frequently cited reasons for using medical marijuana are 
pain, anxiety, sleep problems, nausea, and depression12-14. Canadian studies show as many as 10% of 
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people living with chronic pain15, 14-16% of people with multiple sclerosis16,17, and about 21% of 
people with epilepsy18 use marijuana to manage certain symptoms of their illness. Another Canadian 
study showed that medical marijuana use was reported by 25% of patients with chronic pain, 22% with 
multiple sclerosis, 22% with depression, 21% with arthritis, and 19% with neuropathy19. Further 
conditions and reasons for medical marijuana use found in previous studies include: cancer, HIV, 
glaucoma, Crohn’s disease, hepatitis C, anorexia, cramping, migraine pain, stress, insomnia, and weight 
loss11,12,20.  
 
1.4 Side Effects, Health Risks, and Harms of Medical Marijuana Use 
Studies conducted among medical marijuana users suggest that the most common side effects are 
feeling quiet and mellow, sedated, euphoric, lazy, paranoid, increased appetite, exacerbated 
weakness, hallucinations, and coughing or throat irritation20,21. A small proportion of marijuana users, 
who have used marijuana daily and for many years, experience cannabis hyperemesis syndrome (CHS). 
CHS is characterized by consistent severe episodes of nausea, cyclic vomiting, and abdominal pain3. 
However, generally more than half of users report no side effects from using marijuana and no deaths 
have ever been reported due to a marijuana overdose3,20. 
 
Evidence shows that one in ten individuals who ever use marijuana will experience a dependence 
syndrome22,23. Marijuana dependence syndrome has been found to occur in heavy chronic users and 
includes difficulty controlling their use and continuing to use marijuana despite experiencing negative 
personal consequences23. Additionally, there is some evidence of withdrawal symptoms from 
marijuana use such as irritability, sleeping difficulties, dysphoria, craving, and anxiety. Withdrawal 
4 
 
symptoms indicate the presence of an addiction and also makes cessation more difficult possibly 
contributing to a relapse8.  
 
Marijuana use has been associated with mental illness. Non-medical marijuana users have been 
consistently shown to be at an increased risk of developing psychotic symptoms and disorders6,23. 
Marijuana use itself has not been shown to directly cause schizophrenia; however, marijuana use may 
precipitate or worsen schizophrenia in vulnerable individuals. Brain imaging data shows a correlation 
between regular marijuana use and significantly altered brain structures and functions, which include 
impaired cognition, dysfunctional mood regulation, and reduced memory6. Marijuana use during 
adolescence is particularly concerning given that active brain development occurs throughout these 
youth years making adolescents more vulnerable to the long-term negative effects of marijuana8.  
 
Marijuana use is associated with an increase in the risk of using other harmful drugs, such as cocaine14. 
Epidemiological studies have shown that heavy marijuana use in adolescence may be associated with 
an increased susceptibility to drug abuse and addiction to several other drugs later in life8. One 
explanation may be that previous marijuana use can prepare the brain for a heightened response to 
other drugs as seen in animal studies8. On the other hand, individuals who are more vulnerable to drug 
use behaviours may be more likely to use marijuana first because of its easy availability and would try 
other drugs regardless8. 
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Marijuana use may increase the risk of adverse cardiovascular outcomes, such as tachycardia, 
myocardial infarction, and stroke3. Biological evidence shows that marijuana has detrimental effects on 
vascular resistance and coronary microcirculation, lowers blood pressure, and increases heart rate, 
which puts more stress on the heart2,8. Cardiovascular health risks associated with marijuana use are 
specifically concerning for older medical marijuana users as this treatment may worsen pre-existing 
cardiovascular illness.  
 
Due to a widespread knowledge of the harms associated with smoking tobacco, there is interest in 
understanding the risks associated with smoking marijuana. The combustion of organic materials 
produces very similar chemical profiles; therefore, the toxicants in smoke from marijuana and tobacco 
are similar in many respects23. The health effects from smoke inhalation is closely related to the dose 
and the frequency of use. For example, the typical Canadian cigarette smoker smokes an average of 15 
cigarettes per day. In general, levels of exposure are substantially lower among marijuana users, 
although chronic marijuana smokers may nevertheless present direct health risks. Marijuana smokers 
also inhale unfiltered smoke more deeply and for a prolonged duration of time, at a higher combustion 
temperature, and smoke to a shorter butt length compared to cigarette smokers24. This smoking 
pattern contributes to a five times greater carboxyhaemoglobin concentration, four times greater 
amount of tar inhaled, and one third more tar retained in the lower airway than cigarette smokers25.   
 
Studies have consistently shown that marijuana smokers report a higher frequency of cough and 
sputum production, wheezing, and bronchitis compared with non-smokers as a result of airway 
inflammation and infection26. In addition, some literature reports the presence of lung cancer among 
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marijuana smokers, as well as bullous lung disease and emphysema23,27. It is important to note that 
research examining the long term health effects of marijuana use on the lungs remains limited as it is 
difficult to infer a cause-effect relationship as marijuana users often smoke marijuana in combination 
with tobacco, or are tobacco smokers as well27. Additionally, the time lag between marijuana use and 
disease outcome is long, which makes research more difficult22. 
 
A major concern resulting from marijuana use is the impairment of skills required to operate a motor 
vehicle3. Marijuana use increases the risk of a motor vehicle collision by approximately 2-fold28. 
Evidence has found that after marijuana use, drivers lose control and compensate by driving at 
reduced speeds as well as lane weaving increases, cognitive function is impaired and is reduced with 
increasing task complexity, and reaction times are slower28. However, roadside tests detecting 
marijuana intoxication have low reliability29. Evidence shows that two-thirds of non-medical users had 
ever driven under the influence of marijuana and 41% had done so more than 15 times30.  
 
Additional harms associated with marijuana is that use by pregnant mothers is harmful to the baby 
through in-utero exposure, and marijuana use while breast feeding a baby may also pose negative 
health risks through exposure in the breast milk3. Furthermore, possible harmful drug interactions can 
occur when using marijuana in combination with other medications2,3. 
 
Lastly, it is important to note that most of the risks and harms associated with marijuana use occur in 
those who are frequent, regular, and heavy marijuana users. Harms resulting from marijuana use 
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increase with a higher frequency, increased amounts, and an early age of initiation of using 
marijuana31. The majority of marijuana users in the general population use marijuana infrequently and 
are, therefore, less likely to suffer from marijuana’s negative health effects32. However, medical users 
seem to use more marijuana more often than recreational users, which suggests that greater attention 
should be directed at the medical marijuana population33. 
 
1.5 Marijuana Use in Canada among the General Population  
Currently, marijuana is the most commonly used illegal drug by Canadians34. According to the 2012 
Canadian Alcohol and Drug Use Monitoring Survey, 41.5% of Canadians have reported using marijuana 
at least once in their lifetime34. The prevalence of past-year marijuana use among Canadians aged 15 
years and older was 10.2% in 201234. Past-year marijuana use rates have remained fairly consistent at 
around 10% since 200834. In addition, 6.4% of Canadians reported using marijuana in the past 30 
days35. Frequency of marijuana use reported in the past 3 months was 8%, with 2.2% reporting using it 
less than monthly, 1.7% using it monthly, 2% using it weekly, and 2.1% using it daily35. Overall, the 
province of British Columbia had the highest prevalence of past year marijuana use (13.8%)34. 
 
The prevalence of past year marijuana use among youth (20.3%) continues to be higher than that of 
adults (8.4%)34. In addition, the Ontario Student Drug Use and Health Survey found that in 2013, 
approximately 3% of grade 7-12 students surveyed use cannabis daily and approximately 12% reported 
smoking 4 or more joints in the past month36. 
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1.6 Medical Marijuana Use in Canada 
Legal medical marijuana users have documented approval to use medical marijuana from a healthcare 
practitioner. However, others report using marijuana for medical purposes without having legal 
documentation for approval. For example, the 2011 Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) found that 17.7% of Canadians who used marijuana reported doing so for medical 
purposes34. 
 
The most recent estimate from 2013 claimed there were approximately 40,000 Canadian licensed 
medical marijuana users that year37. In addition, 3 million medical marijuana plants were cultivated 
and it is estimated that the medical marijuana market in Canada alone will increase to about $1.3 
billion by 202437. The majority of Canadians with a medical marijuana license reside in British 
Columbia, accounting for nearly half of all licensed medical users in Canada, followed by Ontario at 
about 30%37. As of 2012, Health Canada reported that 28,115 Canadians had an authorization to 
possess dried marijuana. Of those with authorization, 18,063 Canadians had a personal-use production 
licence, 3,405 Canadians had a designated person production licence, and 5,283 Canadians accessed 
marijuana from authorized companies by Health Canada37. 
 
1.7 Patterns of Medical Marijuana Use 
Evidence shows that the majority of medical marijuana users administer marijuana daily and multiple 
times within each day, with average consumption ranging from 17 to 28 grams per week13,15,38. In 
addition, most medical users identified four or less puffs as a single dose and some others reported 
using one joint as a single dose15. Patterns of medical marijuana use are similar across medical 
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conditions and symptoms13. For example, those using marijuana to relieve pain and others using 
marijuana to control nausea use marijuana in similar frequencies and amounts.  
 
In the general population, marijuana users tend to be younger, male, and with higher reported levels 
of alcohol, tobacco, and other drug use14. Many marijuana users, both medical and non-medical, report 
mixing marijuana with tobacco15. The majority of medical marijuana users have used marijuana for 
non-medical purposes prior to therapeutic use13,38. Additionally, one study of medical marijuana users 
found that they had a higher income and were more likely to have completed high school compared to 
the general Canadian population13.  
 
1.8 Canadian Regulations on Marijuana  
Marijuana is classified as an illegal drug under the Canadian Controlled Drugs and Substances Act39. 
Growing marijuana is punishable by the law of up to seven years imprisonment, possessing marijuana 
up to five years imprisonment, and distributing and selling marijuana up to life imprisonment39. 
Although marijuana is illegal for the general Canadian population, the Canadian courts ruled that there 
must be access to a legal source of medical marijuana to treat patients suffering from medical illnesses. 
The Canadian government had concerns regarding the consequences of allowing access to a legal 
source of medical marijuana as there was an absence of strong evidence of marijuana’s safety and 
efficacy40. In addition, the introduction of medical marijuana laws has been previously associated with 
a higher prevalence of marijuana use among the general public, although this has been debated41,42. 
On the other hand, having a medical marijuana law is also associated with reduced alcohol, illicit 
substance, and prescription drug use43. 
10 
 
In 2001, Health Canada granted access to marijuana for medical purposes to Canadians under the 
Marihuana Medical Access Regulations (MMAR). Those who were licenced through Health Canada had 
three options for obtaining a legal supply of dried marijuana: 1) access Health Canada’s supply of dried 
marijuana; 2) apply for a personal-use production licence; or 3) designate someone to cultivate on 
their behalf with a designated-person production licence44. However, several years into the program, 
few Canadians had obtained MMAR approval and many reported obtaining their supply of medical 
marijuana through illegal sources, suggesting that substantial obstacles with MMAR were present38. 
Some of the problems with the MMAR included, lack of information, product quality concerns, and a 
confusing application process.  
 
In response to concerns of efficacy, and concerns from stakeholders that the MMAR system was open 
to abuse, the Government of Canada introduced the Marihuana for Medical Purposes Regulations 
(MMPR) as of April 1, 2014. Currently, the only legal way to access marijuana for medical purposes is 
through commercial Health Canada licensed producers under the new MMPR. Individuals who are 
legally allowed to use medical marijuana must have a prescription from an authorized healthcare 
practitioner and be registered to order and receive dried medical marijuana from a Health Canada 
licensed producer44.  
 
The MMAR was criticized for having substantial barriers for patients becoming authorized through 
Health Canada. For example, a Canadian study revealed that those who identified anxiety or 
depression as the main condition for using medical marijuana were less likely to be legally authorized 
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to use marijuana for medical purposes by Health Canada under the MMAR compared to those with 
multiple sclerosis and gastro-intestinal conditions13. On the other hand, the new MMPR regulation may 
result in easier access to medical marijuana as physicians have control over who can use medical 
marijuana and physicians may be more flexible with who they give prescriptions to10. The concern has 
been raised that the MMPR may be overly flexible allowing Canadians to be able to claim they need 
marijuana for medical purposes when in reality they want to use marijuana for recreational purposes 
only10. The MMPR is similar to California’s medical marijuana regulation where virtually anyone can get 
a prescription to use marijuana10. In addition, illegal community-based dispensaries continue to be 
provide marijuana to authorized and unauthorized users45,46. 
 
As of July 8, 2015, the Canadian federal courts decided that medical marijuana users have the right to 
use marijuana oils, extractions, and edible marijuana products and that licensed producers may 
produce and sell these forms of marijuana47. A major advantage of having marijuana extracts available 
to medical users are that these products have a higher potency and may be more beneficial to users 
who require higher concentrations of marijuana for relief of symptoms. Extracts can also be used in 
certain types of vapourizers, for consuming marijuana in food, for drinking, and in sprays. However, the 
higher concentrations of cannabinoids in extracts may also increase the risk of some side effects, 
including mental illness, although this is debateable48.  
 
Furthermore, there are currently three synthetic cannabinoid products available in Canadian 
pharmacies through a prescription for medical use. Marinol®, also known by its generic name 
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dronabinol, contains a synthetic THC in pill form; Cesamet® contains another synthetic derivative of 
THC in pill form known as nabilone; and Sativex® is an oral spray containing equal proportions of THC 
and CBD known as nabiximol9.  
 
1.8.1 International Regulations on Marijuana   
Medical marijuana laws have been implemented in a number of other countries in addition to Canada. 
Marijuana laws in the US are individually governed by each state. There are 24 states, including the 
District of Columbia, with medical marijuana laws and 11 states with CBD- specific medical marijuana 
laws49,50. In particular, Minnesota’s medical marijuana legislation allows patients with one of the 
qualifying conditions to use marijuana, but marijuana is only available in non-smokeable forms51. In the 
Netherlands, since September 1, 2003, medical marijuana has been obtainable through pharmacies 
and is produced under the control of the Dutch government52. Additionally, Germany, Italy, and 
Finland allow prescriptions for medical marijuana and import their medical marijuana from the Dutch 
government52. The broader legal context of marijuana use, including decriminalization and legalization, 
also differs by country and may have implications for patterns of use and accessibility of medical 
marijuana. 
 
1.9 Modes of Delivery 
1.9.1 Smoking 
Smoking marijuana is the act of inhaling and exhaling smoke that was produced through combustion of 
marijuana plant material. Marijuana can be smoked in hand-rolled cigarettes (i.e., joints), blunts (i.e., 
cigars that have been emptied of tobacco and refilled with a mixture of marijuana and tobacco), in 
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pipes, or in water pipes (i.e., bongs)1. Smoking marijuana results in the fastest onset of action in 
approximately seven minutes, with higher blood concentrations of cannabinoids compared to other 
modes of delivery, which may contribute to its popularity3,24. In a survey conducted by Hazekamp, 
medical marijuana smokers reported requiring around three grams of marijuana per day and requiring 
a higher number of intakes for an effect compared to those who used oral administration24.  
 
1.9.2 Other: Oral, Oro-mucosal, Topical, and Rectal Administration  
Marijuana can be consumed orally in edibles. Popular edibles include cookies and other baked goods, 
or as tea3. Oral administration results in a slower onset of action and lower peak blood levels of 
cannabinoids compared to inhalation; however, oral use of marijuana requires the fewest number of 
intakes3. The oral route of administration avoids possible negative respiratory health risks associated 
with smoking marijuana, as absorption from consuming marijuana is primarily through the stomach 
and intestines. Similarly, oro-mucosal administration of marijuana is less harmful than smoking. During 
oro-mucosal administration, marijuana is absorbed across the mucous lining in the mouth and is most 
commonly used as sprays, such as the marijuana product nabiximols (Sativex®), or alcohol extractions 
called tinctures. Onset of action occurs much slower in oro-mucosal administration compared to 
inhalation as the peak blood concentration typically occurs within 2 to 4 hours after use and oro-
mucosal administration requires the highest number of intakes3,24. Less widely used modes of delivery 
for marijuana are topically and rectally. Limited research has focused on topical administration of 
marijuana and there are no clinical studies on the use of topicals for therapeutic purposes3.  
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1.9.3 Vapourization 
Vapourizing marijuana is similar to smoking; however, the main difference is that marijuana is heated 
without combustion, thus the user inhales vapour instead of smoke26. Time for onset of action and 
blood concentrations obtained through vapourization are comparable to those obtained by smoking 
marijuana53. In addition, it has been reported that using pure THC in a vapourizer may have a faster 
onset of effects than with herbal marijuana24. Vapourizing requires similar amounts and number of 
intakes of marijuana as smoking24. However, it is difficult to quantify the amount and frequency of use 
with vapourizers as there is no standard for measurement at this time.  
 
Vapourizing marijuana is a possible harm reduction approach, which addresses some of the negative 
health consequences resulting from smoking marijuana. When vapourizing at the proper temperature, 
marijuana is not burned, therefore, harmful by-products like tar, carbon monoxide, and carbon dioxide 
are not released during vapourization as they are in smoking. Five studies show that vapourization of 
marijuana is less harmful and reduces respiratory effects compared to smoking. In 2009, Pomahacova 
analyzed chemical constituents produced by vapourized and smoked marijuana, specifically comparing 
the ratio of cannabinoids to unwanted by-products in vapourized versus smoked marijuana. The 
volcano vapourizer obtained a higher cannabinoid to by-product ratio at 200°C and 230°C than 
smoking, thus showing vapourization provides a cleaner method of marijuana administration 
compared to smoking54. A separate study surveyed current marijuana users and found that 
respondents who vapourized marijuana reported fewer respiratory symptoms such as cough, phlegm, 
and tightness in the chest compared to participants who did not vapourize26. In 2010, a case study of 
four marijuana smokers with at least two respiratory symptoms used a vapourizer to administer 
15 
 
marijuana for one month. All four participants reported improved respiratory symptoms in addition to 
a modest improvement in lung function measurements while using the vapourizer55. Furthermore, a 
similar study with 20 participants, measured respiratory symptoms through self-report and spirometry 
testing and found significant improvements with the use of vapourization compared to smoking 
marijuana56. An inpatient pilot study conducted by Abrams examined 18 healthy marijuana users over 
six days. Carbon monoxide levels were substantially reduced via vapourization compared to smoking 
marijuana with no adverse events observed during vapourization53. However, vapourization of 
marijuana still has health risks associated with its use. A recent study has revealed that the chemical, 
ammonia, is produced at toxic levels when marijuana is heated for vapourization57. 
 
Furthermore, there are two studies that provide emissions evidence of vapourized marijuana obtaining 
similar levels or even greater levels of cannabinoids compared to smoked marijuana. In 2004, Gieringer 
used high-performance liquid chromatography (HPLC) and gas chromatography–mass spectrometry 
(GC-MS) to analyze the vapour produced by the vapourization machine called the Volcano. This study 
found that the Volcano delivered equivalent amounts of THC and cannabinoids to that of marijuana 
cigarettes. Gieringer’s study concluded that vaping marijuana can theoretically deliver therapeutic 
doses of cannabinoids for symptom relief58. The previously discussed study conducted by Pomahacova 
in 2009, also showed that at 200°C, the Volcano vapourizer produced higher levels of cannabinoids 
compared to smoked marijuana54.  
 
Additionally, two biological studies provide evidence that vapourized marijuana obtains similar levels 
of cannabinoids compared to smoking marijuana. In 2006, Hazekamp examined the pulmonary uptake 
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of THC in vapour compared to smoke. Vapourization of marijuana obtained comparable pulmonic 
uptake of THC as smoking25. Furthermore, the Abrams pilot study among current marijuana users 
found that the peak plasma concentrations of THC after inhalation of vapourized marijuana were 
similar to those of smoked marijuana. Moreover, the participants reported similar feelings of euphoria 
during vapourizing and smoking marijuana53. 
 
Overall, research evidence supports vapourization of marijuana as a less harmful alternative to 
smoking marijuana and that comparable levels of cannabinoids are produced by vapourization and 
smoking marijuana for therapeutic effectiveness. Thus, vapourizing marijuana is a potential harm 
reduction approach, which addresses some of the negative health consequences resulting from 
smoking marijuana. 
 
1.9.4 Modes of Delivery among Medical Marijuana users 
Most medical marijuana users have tried multiple modes of delivery for various symptom relief; 
however, smoking predominates as the most common mode of delivery. There are two Canadian and 
four International surveys that examined the diverse modes of delivery for marijuana used by medical 
marijuana users. In a Canadian survey conducted by Ware in 2003, preferred modes of delivery among 
medical marijuana users were 34% joints, 18% skin patches, 16% inhalers, 13% sublingual spray, 8% 
pipes, and one subject indicated that a rectal suppository would be preferred15. A more recent 
Canadian survey showed that among medical users, 96% smoke, 50% consume edibles, about 10% use 
a vapourizer, another 10% ingest a tincture, and only 17 respondents reported using synthetic 
pharmaceuticals38. 
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Studies conducted outside of Canada have found similar patterns regarding modes of delivery used by 
medical marijuana users. For example, an Australian survey found 91% of medical users have tried 
smoking marijuana, 49% had consumed marijuana in edibles, 8% used vapourizers, four people had 
used tinctures, and one participant had used it topically12. Ware conducted a survey in the UK and 
found that 82% of medical users smoked marijuana, 43% consumed marijuana in edibles, 28% 
consumed marijuana as tea, 2% used a sublingual spray, and 12% used other modes of marijuana 
delivery19. In the US, a survey of medical users who were in the process of becoming licensed found 
that most participants preferred inhaled marijuana and that most have not tried edibles59. An 
International cross sectional survey among medical users predominately from the US, Germany, 
France, Canada, The Netherlands, and Spain, found that overall 91.6% had ever smoked, 49.8% had 
used a vapourizer, 87.4% have consumed it in food, 35.4% consumed it in tea, 5% used it topically, and 
the fewest number of participants tried synthetic marijuana24.  
 
1.9.5 Perceptions of Modes of Delivery   
Two Canadian studies have investigated perceptions regarding the modes of delivery for marijuana. 
The first is a Canadian survey of medical marijuana users who reported enjoying smoking marijuana 
and claim that smoking has advantages over other modes of delivery14. Participants stated that 
smoking has a more immediate and effective relief of symptoms, a lower dose is required for effect, it 
is easy to do, and that the euphoria from smoking is felt throughout one’s body and head combined14. 
Some participants stated some disadvantages of smoking marijuana including worrying about the 
respiratory side effects, social aspects, and the smell14. Medical marijuana users in this study reported 
that edibles do not provide the same euphoria and are more expensive than smoking as well as it 
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makes the user feel lazy14. Some advantages that were reported include that edibles provide a longer 
lasting effect and there is no worrying about the smell. Tea is another form of oral administration that 
marijuana users reported using and its effects are perceived to occur faster than when consuming 
edibles14.  
 
The second Canadian study interviewed experienced marijuana users, who used marijuana medically 
and/or recreationally. Participants who preferred smoking joints stated that it is the most convenient 
and easiest mode of delivery to use, provides the best control over dosage, less potent, cleaner and 
tastes better than pipes, is the least stigmatizing, and most social method30. Although less marijuana 
users preferred smoking marijuana through a pipe compared to smoking a joint, those who did prefer 
using a pipe stated it was smoother, more efficient, economical, and gives off fewer contaminants than 
smoking a joint30. Only six percent of participants suggested non-smoking methods to administer 
marijuana. However, some participants acknowledged the harms associated with smoking as they 
mentioned ways to reduce these harms such as, avoid breath-holding prior to exhaling and mixing the 
drug with tobacco30.  
 
International studies also reveal that the popularity of smoking seems to result from its immediate 
onset of effect, ease of titration, and cost-effectiveness12,24. Marijuana users who smoke also report 
high satisfaction in regards to preparation and intake24. However, non-smoking methods are perceived 
as healthier options for administering marijuana 12,24. Marijuana users reported that edibles are tasty 
when cooked in a recipe, less obvious than smoking, can be done virtually anywhere, has long lasting 
effects, and a slow onset, which some participants liked12,24. Other participants claimed difficulties with 
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dose titration and preparation and disliked edibles for their slow onset and expensive cost12,24,59. 
Medical marijuana users who use synthetic methods of administration report that the standardized 
medicine is easy to prepare and administer24. However, users report low dose satisfaction, short 
duration of effects, and multiple negative side effects24.  
 
Vapourizing is perceived as similar to smoking as users report ease of dose titration and fast onset of 
action24. The difference between vapourizing and smoking marijuana occurs with the perceived side 
effects as vapourization is reported to have the least negative side effects compared to all other 
methods of marijuana administration24,60. Vaping has also been reported to taste better, have no 
smoke smell, and is more discreet than smoking. In addition, a study found that participants reported 
their vapourizer experiences as satisfying or very satisfying and that 98% of those respondents 
indicated that they intended to continue using a vapourizer60. Regarding the disadvantages of using a 
vaporizer, users reported that vapourizers are inconvenient, can be difficult to use and setup, and the 
purchase cost is high60. For example, in one study participants who use a vapourizer cited spending a 
mean cost of $251, which ranged from $45 to $700, to purchase a vapourizer60. In addition, only one 
vapourizer is currently approved by Health Canada, called the Volcano, and it comes with a price tag of 
about $6003.  
 
1.10 Forms of Marijuana 
Marijuana is commonly used in the form of a dried herb, but can also been used as hash (i.e., 
marijuana resin), oil, butter (i.e., to cook with), butane extract (e.g., shatter), alcohol extract (i.e., 
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tincture), carbon dioxide (CO2) extract, raw juice, spray (e.g., Sativex/nabiximols), or synthetic 
marijuana created in a lab setting for pharmaceutical purposes (e.g., Marinol®/dronabinol and 
Cesamet®/nabilone)3,24. Dried herb can be converted into these other forms of marijuana. Extracts, 
such as butane, alcohol, and carbon dioxide, are in the form of a wax and have higher THC 
concentrations compared to traditional dried herb forms of marijuana48. Anecdotal evidence suggests 
that extracts can contain THC concentrations of approximately 70% to 90%, whereas dried herb ranges 
between 3% and 6%. However, other estimates suggest that the concentrations of THC in extracts are 
closer to 20% to 25%61. Spray and synthetic marijuana forms can be purchased from pharmacies. The 
form of marijuana used has implications for which modes of delivery can be used; for example, those 
who use dried herb can smoke or use certain vapourizers to administer dried marijuana.  
 
1.11 Novel Technique for Using Marijuana 
Dabbing is a novel technique for using marijuana that has recently become more popular48. The term, 
dabbing, refers to the method where a “dab” of marijuana extract is placed on a pre-heated glass or 
titanium rod, called a nail48. The extract is then vaporized very quickly, allowing the user to inhale the 
vapors to feel its effects. The process of dabbing can be dangerous as pre-heating the nail requires that 
fire is in close proximity to butane, which can cause an explosion, and inhalation of combustion by-
products can occur if the nail is heated to high temperatures48. Although there may be additional 
harms associated with dabbing, there is only one scientific paper that examines the use of dabbing.   
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1.12 Canadians’ Perceptions of Marijuana    
Views on marijuana are more supportive, as it is now well tolerated and widely accessible30. Canadians 
no longer believe that marijuana use is isolated to a specific sub-set of criminals62. A qualitative study 
with focus groups found that in 2002 the general Canadian population favoured decriminalization and 
even legalization of marijuana63. Canadians also indicated strong support for the medical use of 
marijuana in that study63. A survey that also included semi-structured interviews reported that the 
majority of marijuana users criticized the current Canadian laws against marijuana, calling the penalties 
harsh and excessive64. Marijuana users in this study favoured a change of law that would treat 
marijuana the same as alcohol and tobacco; arguing that marijuana was the same or even less harmful 
when compared to alcohol and tobacco64. The perceptions and opinions of the Canadian public may 
impact who uses medical marijuana as a treatment option as well as ways and patterns of using 
marijuana.   
 
The majority of Canadians do not perceive marijuana as dangerous and believe that marijuana use has 
low levels of risk or harm62,65. In a survey of adults, Canadians were more likely to perceive marijuana 
as harmless than adults in Sweden or Finland27. In addition, the Canadian Council of Motor Transport 
Administrators (CCMTA) reported that only 68% of people agreed that marijuana impairs driving66. 
Canadian youth also seem confused about the effects of marijuana. The Canadian Centre on Substance 
Abuse (CCSA) conducted a survey, which found that many youth regard marijuana as natural, safe, 
non-addictive, and do not consider marijuana a drug67. Youth in the study reported perceived positive 
effects of marijuana more often than negative effects67.  
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A survey among Canadian adults found that participants reported some concern regarding the negative 
health risks associated with smoking marijuana14. Some participants stated that they worried about the 
respiratory side effects, including the lungs and throat, and mentioned ways to reduce these harms 
such as, avoid breath-holding prior to exhaling and mixing the drug with tobacco14,30.  
 
Marijuana users themselves believe that if marijuana use is under control and is not interfering with 
one’s responsibilities, then using marijuana is not at all problematic62. Marijuana users reported that 
using marijuana too frequently or consuming excessive quantities is the only way marijuana could 
cause health problems62. Some marijuana users describe their marijuana use as “normal” and that 
using marijuana contributes positive and beneficial aspects to their life, without mentioning explicitly 
what these aspects are62.  
 
1.12.1 Stigma and Support  
Although using marijuana is widely prevalent and accepted, there is still a stigma experienced by some 
users, which may be a potential barrier to the use of medical marijuana30. Stigmatization can come 
from a variety of sources including family, friends, co-workers, bosses, neighbours, and even 
healthcare professionals. Studies show that 60-70% of non-medical marijuana users report hiding their 
use from certain people, most notably parents and other family members30,68. The reasons that were 
given for hiding their marijuana use were respect for the feelings of nonusers and to avoid social 
stigma, but some felt guilty because hiding it had distanced them from others30. 
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Stereotypes persist regarding marijuana’s association with criminality and as a gateway for the use of 
other drugs68. Also, terms like “pothead” and “druggie” are demeaning and non-medical users believe 
these labels have resulted in some status loss or social disapproval. In most cases, however, negative 
reactions from others were reported to be minor and appeared to stem from concern about the 
individual’s inappropriate use of marijuana, such as while driving or before work62. 
 
Individuals who have chosen to use medical marijuana as therapy also report feeling similar stigma as 
non-medical users for their choice. In a recent Canadian study, medical marijuana users reported 
feeling stigma primarily from family members and close friends69. Types of stigma felt were others’ 
beliefs that they are using a recreational drug for pleasure and just for fun, being a criminal, and 
vulnerabilities related to illnesses and disabilities69.  
 
In a Canadian study of HIV/AIDS patients, the majority of physicians supported the patients’ decision to 
use medical marijuana for relief of symptoms38. However, a few patients reported that their physician 
refused to sign their application for a federal authorization to use marijuana medically due to the 
physician’s fear of repercussions from the Canadian Medical Association if they were to sign 
application forms38. Physician support for using medical marijuana may vary depending on the 
patient’s condition(s) and the physician’s training. In fact, physicians, nurses, and other healthcare 
professionals are requesting more information about how and when to prescribe medical marijuana50.  
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2.0 STUDY RATIONALE 
More than 40,000 Canadians are estimated to be approved to access medical marijuana legally34,37 and 
the number of approved medical marijuana users in Canada is expected to increase to 500,000 or 
more10. Most medical users administer marijuana daily and for long durations throughout their 
lifetime, making medical marijuana a public health concern. As Canadian medical marijuana regulations 
continue to change, it is important to examine medical marijuana users’ current trends regarding 
patterns of use and modes of delivery. The modes of delivery among medical users—whether 
marijuana is smoked, consumed, or vapourized—may have important implications for potential 
therapeutic efficacy as well as health risks. Although smoking remains the most common mode of 
delivery for marijuana, anecdotal evidence suggests that the use of alternative and innovative modes 
of delivery is on the rise. The current study addresses this research gap by collecting prevalence data 
for use of novel modes of delivery, such as dabbing. In addition, given recent increases in the 
popularity of vapourizing nicotine through electronic cigarettes, the present study examined the use of 
vapourizers as a mode of delivery for marijuana. New areas of research were explored, such as 
examining the prevalence of different forms of marijuana used by approved medical marijuana users. 
During the study period, Canada had restrictions on the use and sale of medical marijuana to only dried 
herb, which may have had implications for the mode of delivery used as dried herb is most easily 
smoked. The scientific literature claims that smoking marijuana has some negative side effects and 
possible long term consequences, which could be prevented through the use of less harmful modes of 
delivery. Overall, understanding how and why current medical marijuana users select modes of 
delivery, forms of marijuana, and sources of obtaining marijuana may have implications for the 
outcomes of current and future marijuana policies.   
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2.1 Research Questions 
The present study examined modes of delivery used by approved adult Canadian medical marijuana 
users. The study addressed five primary research questions: 
1. What is the prevalence of different modes of delivery among approved medical marijuana 
users? 
2. What are approved medical marijuana users’ perceptions about different modes of delivery and 
what is important to them when selecting a mode of delivery?  
3. What is the prevalence of different forms of marijuana used by medical marijuana users?  
4. Are there differences in the reasons for using different main forms of marijuana? 
5. What are approved medical marijuana users’ prevalence and perceptions of different sources 
for obtaining medical marijuana?  
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3.0 METHODS 
3.1 Study Participants 
An online cross-sectional survey was conducted from April 29 until June 8, 2015. Eligible participants 
were Canadians that were at least 18 years of age, used medical marijuana in the past 30 days, were 
approved to use medical marijuana, and had access to email. Medical marijuana users were defined as 
those who reported using marijuana “for health reasons (i.e., for relief of health symptoms)”. 
Approved medical marijuana users were defined as those who reported that they were currently 
“approved to possess marijuana for health reasons in Canada”.  
 
The online survey underwent cognitive interviewing with approved medical marijuana users (n=3)70. 
The cognitive interviewing was conducted at the University of Waterloo and the interview protocol 
used is in Appendix A. Furthermore, the survey was pre-tested to ensure there were no issues with 
programming (n=8, average time to completion= 48 minutes).   
 
A convenience sample of participants was recruited through Health Canada approved licensed 
producers. An email was sent to all 18 Health Canada licensed producers listed on Health Canada’s 
website asking if they would be willing to invite their clients to partake in our study. Nine Health 
Canada licensed producers were willing to help recruit participants and two Health Canada licensed 
producers were not registering people yet. Although there was limited information regarding licensed 
producers, it seemed as though the licensed producers who helped with recruitment consisted of 
varying numbers of clients and were located across Canada. See Appendix B for a list of licensed 
producers who contributed to recruitment for the study. The Health Canada licensed producers who 
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helped with recruitment sent their clients an email invitation to email marijuanasurvey@uwaterloo.ca 
for a password to complete our medical marijuana survey. Individual passwords that could only be 
used one time were given to interested participants via email. In addition, one Health Canada licensed 
producer invited their clients to complete our survey through social media (i.e., twitter). Participants 
who completed the survey were given $10.00 from their choice of an interac e-transfer or an e-gift 
card from either Starbucks, Indigo/Chapters, Amazon.ca, iTunes, or Cineplex as a thank you for 
completing the survey. The only personally identifying information that was collected from participants 
was an email address used to send their electronic gift card and at no point was the email in the same 
file as the responses. All of the information provided by participants was kept strictly confidential.  
 
3.3 Survey Measures 
The cross-sectional survey included measures for demographic information, patterns of marijuana use, 
marijuana use behaviours, reasons for use, modes of delivery, vapourizer use, and sources used for 
obtaining marijuana. Several previously developed questions were used, adapted, or modified for use 
in the current survey12,24,26,34,71. A copy of the survey including all measures and their sources can be 
found in Appendix C. 
 
3.3.1 Screening Questions  
Prior to the start of the survey, participants were provided with the statement: “In this survey, when 
we use the term marijuana, we mean marijuana in any form including hashish, hash oil, synthetics, or 
other marijuana derivatives (e.g., edibles, extracts). Also, when we use the phrase ‘marijuana for 
health reasons’, we mean the use of marijuana for relief of health symptoms, also known as “medical 
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marijuana”. This statement is meant to clarify the term marijuana as well as the phrase used to 
describe marijuana use for medical purposes to reduce any confusion.  
 
Before participants began the survey, four questions were asked to ensure eligibility. Participants were 
asked to “please enter your age” and responses were provided in the space available. Participants 
were asked, “In the PAST 30 DAYS, have you used marijuana?” with responses ‘Yes’, ‘No’, ‘Don’t know’, 
and ‘Refuse to answer’. Participants were asked, “In the PAST 30 DAYS, have you used marijuana…” 
with responses ‘For health reasons only (i.e., for relief of health symptoms)’, ‘For recreational purposes 
only (i.e., to get high, to be social)’, ‘For both health and recreational purposes?’, ‘Don’t know’, and 
‘Refuse to answer’. Lastly, participants were asked, “Are you CURRENTLY approved to possess 
marijuana for health reasons in Canada?” with responses ‘Yes’, ‘No’, ‘Don’t know’, and ‘Refuse to 
answer’. Eligible participants were 18 years of age or older, responded ‘yes’ to using marijuana in the 
past 30 days, used marijuana ‘for health reasons only (i.e., for relief of health symptoms) or ‘for both 
health and recreational purposes’, and responded yes to being an approved medical marijuana user in 
Canada.   
 
3.3.2 Demographic Information  
Demographic information was collected in the survey and included age, gender (1=male, 2=female), 
region (1= Atlantic: New Brunswick, Newfoundland & Labrador, Nova Scotia, Prince Edward Island; 2= 
Quebec; 3=Prairies: Alberta, Manitoba, Saskatchewan; 4= British Columbia; 5= Ontario and Northern: 
Ontario, Northwest Territories, Nunavut), ethnicity (1=white, 0= Mixed/Other/Missing), education 
(0=low: grade school, some high school, completed high school; 1= moderate: technical/trade school 
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or community college and some university, no degree; 2= high: completed university degree and 
masters, PhD or other post-graduate degree), income (0=low: less than $20,000 and $20,000 to 
$40,000; 1=middle: $40,001 to $60,000 and $60,001 to $80,000; 2=high: $80,001 to $100,000 and 
more than $100,000), and cigarette smoking status (0=not at all, 1=occasionally, 2=daily).  
 
3.3.3 Medical Reasons for Marijuana Use  
Medical reasons for marijuana use were examined including, the main medical reason marijuana was 
used for (1=pain relief: chronic pain and fibromyalgia; 2=mental health: anxiety or nerves, depression, 
ADHD, bipolar, PTSD; 3=central nervous system: multiple sclerosis and spinal cord injury and epilepsy; 
4=side effects: nausea or vomiting and lack of appetite or weight loss; 5=other: other, glaucoma, 
cancer, insomnia). In addition, participants were asked if they have a life threatening medical condition 
with a prognosis of less than one year and if they have any respiratory illnesses (e.g., asthma, COPD, 
lung cancer).  
 
3.3.4 Side Effects of Medical Marijuana Use 
Self-reported respiratory symptoms were examined using six previously adapted questions26. 
Participants who responded ‘yes’ or ‘sometimes’ to each of the six questions received a 1 and those 
who responded no received a 0. A sum of all six questions was used to assess participants’ level of 
respiratory symptoms. Moreover, participants were asked, “What effects have you ever experienced 
from using marijuana for health reasons?” and selected responses from a list of side effects. After 
stating, “the next question asks about SMOKING marijuana, as a joint, blunt, in a pipe, bong, 
waterpipe, etc.” participants were asked to report their perceived harm from smoking marijuana 
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(0=low: not at all harmful to their health; 1=moderate: a little or somewhat harmful to their health; 
2=high: very or extremely harmful to their health). 
 
3.3.5 Patterns of Medical Marijuana Use 
Participants were asked about their frequency of marijuana use in the past three months with 
response options including ‘Every day’, ‘Almost every day’, ‘At least once a week’, ‘At least once a 
month’, ‘Less than once a month’, ‘Don't know’, and ‘Refuse to answer’. Participants were asked “In 
the past 30 days, on average, on how many of these days did you use marijuana (for any reason)?” and 
“In the past 30 days, on average, on the days that you used marijuana (for any reason), how many 
times per day did you use it?” Furthermore, how much marijuana participants used was assessed by 
first asking participants whether it is easier to say how much marijuana they use per day, per week, or 
per month. Participants were then asked to report on average, how many grams of marijuana they use 
per day, per week, or per month. The use of marijuana combined with tobacco was examined as well 
as the amount of marijuana that was used for recreational purposes.  
 
3.3.6 Prevalence of Modes of Delivery  
Ever, Current (i.e., past 30 day use), Preferred modes of delivery, and percentage of use for multiple 
modes of delivery were examined in the present survey. An example of a mode of delivery prevalence 
question is, “Have you EVER tried or used marijuana in the following ways?” with a list to select as 
many as apply consisting of ‘Smoking a joint’, ‘Smoking a blunt’, ‘Smoking a pipe’, ‘Smoking a bong or 
waterpipe’, ‘Using a vapourizer’, ‘Eating in foods or baked goods (e.g., cookies, candy)’, ‘Drinking (e.g., 
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tea)’, ‘Taking a pill (e.g., Marinol®/ dronabinol or Cesamet® / nabilone)’, ‘Using a spray (e.g., 
Sativex/nabiximols)’, ‘Other (please specify)’, ‘Don’t know’, or ‘Refuse to answer’.  
 
3.3.7 Perceptions and Personal Importance of Factors by Mode of Delivery  
Perceptions of modes of delivery were examined by asking participants to rate 12 factors on a scale 
from 1 to 5 for the modes of delivery ‘smoking’, ‘using a vapourizer’, and ‘eating in foods’, separately. 
Additionally, participants were asked to rate the importance of reasons for selecting modes of delivery 
on a scale from 1 to 5 by answering, “How important are each of the factors to you in your choice of 
how to use marijuana”. The 12 factors to be rated in both questions include: duration of effect (i.e., 
how long it lasts), time to onset of effect (i.e., how quickly the effects occur), the amount of marijuana 
needed for effect, ease of use, ability to find correct dose, symptom relief, number of side effects, type 
of “high”, level of harm, accessibility (i.e., how easy it is to get), cost (i.e., affordability), and stigma (i.e., 
what other people think). Each of these measures were analyzed independently.   
 
3.3.8 Forms of Medical Marijuana   
Participants reported Ever, Current, and Main forms of marijuana used. The list of responses included: 
‘Dried herb’, ‘Marijuana resin (i.e. hash, kief, trichomes)’, ‘Butter (i.e., to cook with)’, ‘Oil’, ‘Alcohol 
extract (i.e., tincture)’, ‘Butane extract (i.e., shatter, wax, dabs)’, ‘Carbon dioxide (CO2) extract’, ‘Raw 
juice’, ‘Prescription marijuana (e.g., Marinol®/ dronabinol, Cesamet® / nabilone, Sativex/nabiximols)’, 
‘Other (please specify)’, ‘Don’t know’, and ‘Refuse to answer’. Participants were also asked, “Why do 
you mainly use [fill in selected option from Main form] form of marijuana?” and selected the reasons 
they use their specific Main form that applied.   
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3.3.9 Novel Techniques for Using Medical Marijuana 
The technique of dabbing marijuana was assessed by asking participants, ‘Have you EVER heard of 
DABBING marijuana?’ and ‘Have you EVER tried DABBING marijuana?’.  
 
3.3.10 Cost 
Participants were asked to report the average cost of marijuana and provide the percentage that was 
covered. 
 
3.3.11 Vapourizers 
All participants were asked whether they were aware of vapourizers for marijuana. Among participants 
who were aware of vapourizers, they were also asked for their perceptions about acceptability and 
harm of vapourizers. Participants who reported using a vapourizer were asked for their patterns of use 
(i.e., form, frequency, and type) as well as reasons for use. Among those participants who had not Ever 
tried a vapourizer with marijuana, the barriers of using a vapourizer were assessed as well as their 
interest level for future vapourizer use.  
 
3.3.12 Sources for Obtaining Marijuana  
Accessibility of marijuana for medical purposes was investigated by asking participants to report Ever, 
Main, and Preferred sources used to access medical marijuana. Furthermore, participants were asked 
to rank the sources for obtaining marijuana ‘from a Health Canada licensed producer’, ‘grow it 
yourself’, and ‘from another non-licensed source (e.g., friends, family, dealer)’ on eight factors, which 
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include cost, time to obtain, accessibility (i.e., how easy it is to get), safety standards, quality (i.e., look, 
feel, smell), potency, symptom relief, and stigma (i.e., negative thoughts from other people), 
separately. 
 
3.3.13 Trap Question 
All participants were required to answer a trap question in order to ensure participants were engaged 
and were putting a sufficient level of thought into answering the survey questions. The inclusion of a 
trap question in online surveys has been highlighted as a good practise to measure validity of 
participants answers (ESOMAR/GRBN. March 2015. Guideline for Online Sample Quality). The trap 
question asked was, “What month are you completing this survey in?” and participants selected a 
month from a list, which also included “Don’t know” and “Refuse to answer” options. Participants who 
answered the trap question wrong were deleted from the analysis.   
 
3.4 Analysis 
The analysis examined five primary hypotheses:  
 
Hypothesis 1— Prevalence of Modes of Delivery: We hypothesize that smoking will be the most 
common Ever, Current, and Preferred mode of delivery. To test this hypothesis, frequencies were 
calculated.  
 
Hypothesis 2 – Perceptions of Modes of Delivery:  We hypothesize that there will be significant 
differences in the perceptions of the three modes of delivery: smoking, using a vapourizer, and eating 
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in food. Specifically, we hypothesize that participants will perceive smoking as having a faster time to 
onset of effect, more accessible, and a better type of “high”; using a vapourizer will be easier to use 
and have less side effects; and eating in foods will require a higher amount of marijuana for effect and 
have a longer duration of effect. We hypothesize that perceived cost will not differ between smoking, 
using a vapourizer, and eating in food. An ANOVA was used to examine differences in perceptions of 
the three modes of delivery. 
 
Hypothesis 3 – Prevalence of Forms of Medical Marijuana: We hypothesize that the most common 
Ever, Current, and Main form of marijuana will be dried herb. To test this hypothesis, frequencies were 
calculated.  
 
Hypothesis 4 – Reasons for Using a Main Form: We hypothesize that those who use dried herb as their 
Main form will be more likely to report the reasons: more accessible, easy to find the correct dose, and 
effects occur faster than those who use alternative Main forms. We hypothesize that those who use 
alternative Main forms will be more likely to report the reasons: more potent, effects last longer, and 
less side effects than those who use dried herb as their Main form. We also hypothesize that there will 
be no difference between reasons for using dried herb or alternative forms for affordability or quality. 
A bivariate Pearson chi-square test was used to examine reasons for choosing to use a Main form of 
marijuana.  
 
Hypothesis 5 – Comparison of Main Sources for Obtaining Medical Marijuana: We hypothesize that 
there will be significant differences between obtaining marijuana from Health Canada licensed 
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producers compared to grow it yourself and non-licensed sources. Specifically, we hypothesize that 
participants will be more likely to report that obtaining marijuana from Health Canada licensed 
producers has high costs, long wait times for receiving their marijuana, high safety standards, is more 
accessible, and low stigma (i.e., what other people think). An ANOVA was conducted to compare 
differences between three Main sources for obtaining medical marijuana. 
 
Overall, a final sample of 364 participants were included in the analyses. Although a total of 400 
participants completed the survey, participants with incorrect or missing information for age (n=1), 
gender (n=8), and the trap question (n=27) were excluded. A total of 555 participants were provided a 
password to access the survey; however, six of those participants were not eligible and 113 did not 
complete the survey. Thus, the survey’s completion rate (COMR) was calculated to be 79.4% using The 
American Association for Public Opinion Research standards (The American Association for Public 
Opinion Research. 2015. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for 
Surveys. 8th edition. AAPOR).  
 
All analyses were conducted using SPSS, Version 22 (IBM, Illinois). Descriptive statistics (means, 
standard deviation, and proportions) are reported for all primary outcomes and covariates. In addition 
to the primary hypotheses tests described above, logistic regression models examined correlates for a 
total of four outcomes: 1) Current modes of delivery (0=smoked only, 1=alternative), 2) Main Form of 
marijuana (0=alternative, 1=dried herb), 3) Current use of vapourizers (0= non-current use of a 
vapourizer, 1=current use of a vapourizer), and 4) Main source (0=other source, 1=Health Canada 
licensed producer). The following set of covariates were “forced” into each model: age, gender, 
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ethnicity, education, total personal income, main medical reason, perception of harm of smoking, and 
respiratory symptoms with the addition of smoking status included as a covariate for the first logistic 
regression model. For the purposes of models, participants from Northern regions (n=1) were grouped 
with Ontario due to limited numbers as Ontario had the largest sample. Odds ratios (OR) and 95% 
confidence intervals (95% CI) are reported for all models. List-wise deletion was used in the case of 
missing data for each logistic regression model. The study received approval from the Office of 
Research Ethics at the University of Waterloo. 
 
3.4.2 Power Calculation 
A power calculation is presented for the total sample (N=364). A sample size of 364 provides 80% 
power to detect a difference of 13.5% for prevalence of modes of delivery between sub-groups (e.g., 
25.0% vs. 38.5%) with equivalent sample sizes (e.g., 182 in each group) for a 2-sided t-test, where 
α=.05.  
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4.0 RESULTS 
4.1 Sample  
Table 1 shows sample characteristics. As Table 1 indicates, more than half of the sample was male, 
approximately 75% was white, more than half were low income, and approximately half lived in 
Ontario. 
 
Table 1: Sample Characteristics (N=364) 
Characteristics                  Sample 
  
               Mean (SD) 
Age (years)          40.8   (12.6) 
         Range: 18-71 
  
                   %  (n) 
Gender  
Male 57.7   (210) 
Female 42.3   (154) 
  
Ethnicity  
White only 74.7   (272) 
Mixed/Other/Missing 25.3     (92) 
  
Education   
Low 29.1   (106) 
Moderate 46.7   (170) 
High         22.0     (80) 
Not reported  2.2       (8) 
  
Income   
Low  58.5   (213) 
Middle             18.1     (66) 
High            14.0     (51) 
Not reported            9.4     (34) 
  
Region  
Ontario 50.3   (183) 
British Columbia       15.1     (55) 
Atlantic             13.2     (48) 
Prairies             13.0     (47) 
Quebec              4.1     (15) 
Northern             3.8    (14) 
Missing              0.5      (2) 
  
Cigarette smoking status  
Not at all 58.5   (213) 
Occasionally            16.2     (59) 
Daily             19.2     (70) 
Missing             6.1     (22) 
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Licensed Producer  
Bedrocan Canada Inc         24.7   (90) 
MariCann Inc          20.3   (74) 
Broken Coast Cannabis             12.4   (45) 
Whistler Medical               12.1   (44) 
MedReleaf Corp           6.6    (24) 
Peace Naturals Project Inc.             4.1    (15) 
Tilray              4.1    (15) 
CanniMed Ltd            3.6    (13) 
Delta 9 Bio Tech Inc                3.6    (13) 
Tweed                3.3    (12) 
Aphria               3.0    (11) 
Mettrum Ltd             2.7    (10) 
CannaFarms Ltd               1.6      (6) 
Organigram             1.4      (5) 
In The Zone Produce Ltd             1.1      (4) 
Missing              5.5   (20) 
 
4.2 Medical Reasons for Marijuana Use 
Table 2 lists the main medical reasons that participants reported treating with medical marijuana. Pain 
relief was the most common medical reason treated by medical marijuana as shown in Table 2. 
 
In addition, participants were asked whether they were using medical marijuana to treat a life 
threatening condition with a prognosis of less than one year. Overall, 5.2% (n=19) reported treating a 
life threatening condition with medical marijuana, whereas 85.4% (n=311) did not have a life 
threatening condition, 4.1% (n=15) didn’t know, and 5.2% (n=19) refused to answer.  
 
Participants also reported whether they had a respiratory illness and a total of 13.7% (n=50) of 
participants reported having a respiratory illness (e.g., asthma, COPD, lung cancer), 74.5% (n=271) did 
not have a respiratory illness, 7.7% (n=28) reported not knowing, and 4.1% (n=15) refused to answer. 
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Table 2: Main Medical Reasons Treated with Medical Marijuana (N=364) 
Main Medical Reason % (n) 
  
Pain Relief   
Chronic pain 42.3   (154) 
Fibromyalgia 2.5       (9) 
  
Mental Health   
Anxiety or nerves 7.4     (27) 
Depression 3.8     (14) 
ADHD 1.4       (5) 
Bipolar 0.3       (1) 
PTSD 2.2       (8) 
  
Central Nervous System   
Multiple sclerosis or spinal cord injury 5.8    (21) 
Epilepsy  4.1    (15) 
  
Side Effects    
Nausea or vomiting 1.9     (7) 
Lack of appetite or weight loss 1.1     (4) 
  
Other   
Other 4.1   (15) 
Glaucoma  0.5     (2) 
Cancer 1.4     (5)  
Insomnia  6.3   (23) 
  
Don’t know 8.5   (31) 
Refuse to answer 6.3   (23) 
  
 
4.3 Side Effects of Medical Marijuana Use 
Participants were asked to report whether they experienced any of six respiratory symptoms. In total, 
38.7% (n=141) of participants did not have any respiratory symptoms, 16.2% (n=59) experienced one 
respiratory symptom, 16.5% (n=60) experienced two respiratory symptoms, 11.6% (n=42) experienced 
three respiratory symptoms, 10.4% (n=38) reported experiencing four respiratory symptoms, 4.7% 
(n=17) reported experiencing five respiratory symptoms, and 1.9% (n=7) reported experiencing all six 
respiratory symptoms.  
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Perception of harm from smoking marijuana was also examined. Among those who had ever tried 
smoking, 21.9% (n=59) perceived the harm from smoking marijuana as Low, 65.1% (n=176) perceived 
the harm from smoking marijuana as Moderate, and 13.0% (n=35) perceived the harm from smoking 
marijuana as High. 
 
Table 3 shows side effects experienced by participants. The most common side effect reported was 
feeling high, followed by increased appetite and dry mouth. 
 
Table 3: Effects of Medical Marijuana Use (N=364) 
Effects  %   (n) 
  
Feeling high 59.3    (216) 
Increased appetite 56.3    (205) 
Dry mouth 51.1    (186) 
Drowsiness or laziness 47.5    (173) 
Confused or forgetful thinking  23.4      (85) 
Feeling quiet or disconnected  20.9      (76) 
Anxiety 14.0      (51) 
Increased heart rate or palpitations 12.4      (45) 
Dehydration 9.9      (36) 
Loss of appetite 8.8      (32) 
Headache 8.2      (30) 
Loss of balance 8.2      (30) 
Paranoia or hallucinations 6.3      (23) 
Sweating 6.0      (22) 
Slurred speech 5.8      (21) 
None 5.2      (19) 
Blurred vision 4.9      (18) 
Nausea 4.9      (18) 
Shaking 4.7      (17) 
Weakness 3.6      (13) 
Other  2.2        (8) 
Don’t know 4.4      (16) 
Refuse to answer 4.1      (15)  
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4.4 Patterns of Medical Marijuana Use 
Patterns of medical marijuana use, including amount and frequency, are shown in Table 4. Additionally, 
participants were asked about their recreational use of marijuana. Overall, 86.3% (n=314) of 
participants reported using marijuana for health purposes only and 13.7% (n=50) of participants 
reported using marijuana for both health and recreational purposes. Among those who reported using 
marijuana for both medical and recreational purposes, the average amount of use for recreational 
purposes was 30.7%. 
 
Table 4: Patterns of Medical Marijuana Use (N=364) 
Characteristic  Mean  (SD) 
  
Amount (g/day) 1.8  (1.6) 
Range (0.1 – 10.5) 
  
 %      (n) 
  
Past 3 month frequency   
Less than once a month 3.3    (12) 
At least once a month 6.5    (24) 
At least once a week 10.2    (37) 
Almost every day 21.2    (77) 
Every day 55.8  (203) 
Don’t know/Refuse to answer   3.0    (11) 
  
Number of times per day*   
Once 15.9   (58) 
Twice  18.1   (66) 
3 times  24.5   (89) 
4-5 times 21.7   (79) 
More than 5 times 18.1   (66) 
Don’t know/Refuse to answer   1.7     (6) 
  
Mixing tobacco with marijuana   
Never 70.3   (256) 
Sometimes 15.4     (56) 
Often 5.5     (20) 
Always 2.0       (7) 
Don’t know/Refuse to answer  6.8     (25) 
  
*Number of times per day represents the average number of times that medical marijuana was used per day on 
the days that medical marijuana was used in the past 30 days. 
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4.5 Prevalence of Modes of Delivery  
Table 5 shows the prevalence of Ever, Current, and Preferred modes of delivery. The most common 
Ever mode of delivery tried was smoking a joint, whereas using a spray was the least common Ever 
mode of delivery tried. Participants (n=295) reported Ever use of a mean of 5.4 (SD=2.2) modes of 
delivery, which ranged from 1 to 10 modes (not shown in the table). 
 
Table 5 also shows the most common Current and Preferred mode of delivery was a vapourizer. 
Participants (n=294) reported Current use of a mean of 2.4 (SD=1.3) modes of delivery with a range 
from 1 to 7 modes. Among those who reported Current use of more than one mode of delivery, the 
mode of delivery used most often was smoking a joint 53.1% (SD=36.8) of the time, followed by 52.4% 
(SD=36.4) using a vapourizer, 43.5% (SD=39.6) other, 36.1% (SD=31.4) smoking a bong or waterpipe, 
31.6% (SD=31.8) smoking a pipe, 26.4% (SD=25.8) taking a pill, 25.0% (SD=29.3) eating in foods or 
baked goods, 22.6% (SD=29.0) drinking, 20.0% (SD=10.8) using a spray, and 13.5% (SD=13.4) smoking a 
blunt.  
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Table 5: Prevalence of Modes of Delivery (N=364) 
Mode Ever Use Current Use Preferred  
 %  (n) %  (n) %  (n) 
    
Smoked modes    
Smoking a joint 74.2   (270) 47.0   (171) 23.1     (84) 
Smoking a pipe 61.3   (223) 25.8     (94) 4.9     (18) 
Smoking a bong/waterpipe 53.6   (195) 21.4     (78) 8.5     (31) 
Smoking a blunt 38.7   (141) 4.7     (17) 1.1       (4) 
At least one smoked 77.2   (281) 58.8  (214) 37.6  (137) 
    
Alternative modes    
Using a vapourizer 65.9   (240) 52.7   (192) 28.3   (103) 
Eating in foods 64.1   (234) 31.0   (113) 7.1     (26) 
Drinking 29.9   (109) 5.5     (20) 1.6       (6) 
Taking a pill 28.6   (104) 3.3     (12) 0.8      (3) 
Using a spray 8.2     (30) 1.1       (4) 0.3      (1) 
Other 10.4     (38) 8.0     (29) 4.7    (17) 
At least one alternative  76.1   (277) 63.7   (232) 42.9   (156) 
    
Don’t know 9.6     (35) 9.6     (35) 10.4    (38) 
Refuse to answer 9.6     (35)  9.9     (36) 9.9    (36) 
    
 
A logistic regression model (see Appendix D: Table 12) was fitted to examine factors associated with 
Current modes of delivery where 1=exclusive use of an alternative mode (n=51) and 0=use of at least 
one smoked mode (n=199) (x2= 76.39, p<0.001, Nagelkerke's R2= 0.41). Significant differences were 
found for education: participants with a high level of education had an increased odds of currently 
using an alternative mode of delivery than those with a low level of education (OR=4.92, 95%CI: 1.44-
16.84, p=0.01) and those with a moderate level of education (OR=5.00, 95%CI: 1.43-16.67, p=0.01), 
whereas participants with low and moderate levels of education did not differ (OR=1.40, 95%CI: 0.44-
4.36, p=0.59). Those who use medical marijuana mainly for other reasons had an increased odds of 
using alternative modes of delivery compared to pain relief, mental health illnesses, and central 
nervous system illnesses (OR=3.41, 95%CI: 1.08-10.70, p=0.04, OR=9.09, 95%CI: 1.96-33.33, p=0.01, 
and OR=16.67, 95%CI: 2.04-100.00, p=0.01, respectively) and those who use medical marijuana for 
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relief of side effects had an increased odds of using alternative modes of delivery compared to mental 
health illnesses and central nervous system illnesses (OR=8.91, 95%CI: 1.05-75.72, p=0.05 and 
OR=17.54, 95%CI: 1.33-231.28, p=0.03, respectively). Participants who perceived the harm from 
smoking marijuana as high had an increased odds of currently using alternative modes of delivery than 
those who perceived the harm from smoking marijuana as low (OR=16.90, 95%CI: 3.88-73.62, p<0.01) 
or moderate (OR=16.67, 95%CI: 2.13-100.00, p<0.01); however, those who perceived the harm from 
smoking marijuana as low or moderate did not significantly differ (OR=2.80, 95%CI: 0.85-9.18, p=0.09). 
Those who reported having a lower number of respiratory symptoms had a higher odds of currently 
using alternative modes of delivery (OR= 1.61, 95%CI: 1.16-2.17, p<0.01). Those who reported a 
cigarette smoking status of not at all or occasionally had higher odds of using alternative modes of 
delivery compared to daily smokers (OR=6.25, 95%CI: 1.56-25.00, p=0.01 and OR=6.23, 95%CI: 0.38-
23.83, p=0.01, respectively), but did not differ compared to each other (OR=0.48, 95%CI: 0.87-2.65, 
p=0.40). Current use of smoked versus alternative modes of delivery did not differ by gender, age, 
ethnicity, income, or region.  
 
4.6 Perceptions of Modes of Delivery  
Participants were asked to rate three modes of delivery—smoking, using a vapourizer, and eating in 
food—along 12 different factors, using a scale ranging from 1 to 5 for each factor. Figure 1 (and 
Appendix D: Table 13) show the mean rating by mode of delivery for each of the 12 factors. ANOVA 
models were run to test for differences in the mean rating between the three modes for each of the 12 
factors. As indicated by the superscript letters in Figure 1, time to onset of effect was rated as 
significantly faster for smoking, followed by using a vapourizer and then eating in food. Smoking was 
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rated as significantly lower cost and more accessible than using a vapourizer or eating in food. 
However, using a vapourizer and eating in food was rated as having a lower level of perceived harm 
than smoking. Using a vapourizer was rated as easiest to use and the number of side effects was rated 
significantly lower for using a vapourizer compared to smoking or eating in food. Eating in foods was 
rated as producing the worst high, most stigma, was the hardest to find a correct dose, but had the 
longest duration of effect. Lastly, perceptions of symptom relief did not differ by mode. The ANOVA 
output for perceptions of modes of delivery by factor is presented in Appendix D: Table 14. 
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Figure 1. Rating of Factors by Modes of Delivery (n=342) 
 
*Rating was completed on a scale from 1 to 5, where 1 represented the least desired effect and 5 represented the most desired effect.  
a,b,c Means with the same letter are significantly different at a p<0.05 tested using an ANOVA.  
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4.7 Personal Importance of Factors by Mode of Delivery 
Participants were asked to rate the importance of each factor in their choice of how to use marijuana. 
Table 6 shows the mean rating of importance provided for each factor. Symptom relief was rated as 
the most important factor when selecting mode of delivery, followed by cost, whereas the least 
important factor was stigma.  
 
Table 6: Rating of Importance for Factors for Selecting Modes of Delivery (N=364)* 
Factors Rating of Importance 
 Mean (SD) 
  
Symptom relief 4.5    (0.9) 
Cost 4.2    (1.0) 
Duration of effect  4.1    (1.0) 
Accessibility 4.0    (1.1) 
Amount needed for effect 4.0    (1.1) 
Time to onset of effect 4.0    (1.1) 
Ability to find correct dose 4.0    (1.1) 
Ease of use 3.9    (1.1) 
Type of “high”  3.8    (1.2) 
Number of side effects 3.7    (1.3) 
Level of harm 3.6    (1.4)  
Stigma 2.6    (1.4)  
  
*Rating was completed on a scale from 1 to 5, where 1 represented not important at all and 5 represented 
extremely important.  
 
4.8 Prevalence of Forms of Medical Marijuana  
Participants reported their Ever, Current, and Main use of different forms of marijuana. Table 7 shows 
the prevalence of Ever, Current, and Main forms of marijuana and indicates that dried herb was the 
most prevalent form used overall. Participants (n=300) reported Ever using a mean of 3.9 (SD=2.0) 
forms of marijuana and Current use of 1.8 (SD=1.1) forms of marijuana (n=299). Participants were 
asked whether they would use the form, extracts, if they were available and 77.3% (n=279) of 
participants reported yes and 22.7% (n=82) reported no.   
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Table 7: Prevalence of Forms of Medical Marijuana (N=364) 
Form Ever Use Current Use Main 
 %  (n) %  (n) %  (n) 
    
Dried herb 79.7   (290) 75.0   (273) 67.6   (246) 
    
Alternative Forms     
Butter   51.6   (188) 20.0     (73) 3.0     (11) 
Marijuana resin  56.9   (207) 15.1     (55) 1.6       (6) 
Oil 46.2   (168) 10.4     (38) 1.4       (5) 
Prescription marijuana  32.1   (117) 10.2     (37) 4.1     (15) 
Butane extract  21.2     (77) 8.0     (29) 1.6       (6) 
Alcohol extract  23.1     (84) 3.8     (14) 1.1       (4) 
Raw juice 5.8     (21) 0.8       (3)            0.0  
CO2 extract 7.7     (17) 0.3       (1) 0.3      (1) 
Other 3.6     (13) 2.7     (10) 1.1      (4) 
    
Don’t know  11.0     (40) 11.3    (41) 11.3   (41) 
Refuse to answer 6.6     (24) 6.6    (24) 6.6   (24) 
Missing   0.0       0.0 0.3     (1) 
    
  
A logistic regression model (Appendix D: Table 15) was fitted to examine factors associated with the 
Main form of marijuana where 1=Main use of dried herb (n=208) and 0=Main use of alternative forms 
(n=39) (x2= 20.71, p=0.30, Nagelkerke's R2=0.14). Participants who perceived the harm of smoking 
marijuana as high had a significantly higher odds of using alternative forms as their Main form of 
marijuana compared to those who perceived the harm from smoking as low (OR=5.88, 95%CI: 1.59- 
20.00, p<0.01) or moderate (OR=3.58, 95%CI: 1.37- 9.09, p<0.01), but those who perceived the harm 
from smoking as low and moderate did not differ. Significant differences were not found for age, 
gender, ethnicity, education, income, region, main medical reason, or respiratory symptoms. Although 
age was not significantly different, a trend occurred in which older people had an increased odds of 
using alternative forms of marijuana (OR=1.03, p=0.09).  
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4.9 Reasons for Using a Main Form  
Participants reported their reasons for choosing to use a specific Main form of marijuana. Table 8 
shows reported reasons for using a Main form among all participants (i.e., overall), among those who 
reported using dried herb as their Main form of marijuana (as shown in Table 7), and among those who 
reported using an alternative form (e.g., butter, marijuana resin, oil, butane extract, alcohol extract, 
CO2 extract, prescription marijuana, other—as shown in Table 7) as their Main form of marijuana. 
Overall, the most common reason for choosing to use a specific Main form of marijuana was that it is 
easy to use, followed by more accessible and best symptom relief. A chi-square test was used to 
examine differences in frequencies of reasons for using a Main form of marijuana comparing 
participants who used dried herb to those who used alternative forms. Participants reported that dried 
herb was significantly more accessible than alternative forms, which was the most common reason for 
using dried herb as their Main form of marijuana. On the other hand, participants reported that 
alternative forms of marijuana had effects that last significantly longer, have significantly less side 
effects, had significantly higher quality, and were significantly less harmful than dried herb. No 
differences were observed for the remaining reasons for use. The chi-square test output for reasons 
for using a Main form between dried herb and alternative forms is shown in Appendix D: Table 16. 
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Table 8: Reasons for Using a Main Form Overall (n=300) and Between Dried Herb (n=246) and Alternative 
Forms (n=52) 
Reasons Overall Dried Herb Form Alternative Form  
    
 %  (n) %  (n) %  (n) 
    
Easy to use 63.3   (190) 65.0   (160) 57.7   (30) 
More accessible  60.7   (182) 66.7   (164) 34.6   (18)* 
Best symptom relief 46.3   (139) 45.5   (112) 51.9   (27) 
Easy to find dose 45.3   (136) 45.9   (113) 44.2   (23) 
Effects occur faster    43.0   (129) 45.1   (111) 34.6   (18) 
Uses less marijuana 32.7     (98) 34.6     (85) 25.0   (13) 
Effects last longer 31.0     (93) 24.8     (61) 59.6   (31)* 
More affordable 30.3     (91) 31.3    (77) 26.9   (14) 
Less side effects 28.0     (84) 24.4    (60) 46.2   (24)* 
Provides the best high 27.3     (82) 26.8    (66) 28.8   (15) 
Higher quality 21.0     (63) 18.7    (46) 32.7   (17)* 
More potent 18.3     (55) 16.7    (41) 26.9   (14) 
Less harmful 18.0     (54) 11.8   (29) 46.2   (24)* 
Recommended to me 18.0     (54) 16.7   (41) 25.0   (13) 
Other    2.7       (8)   1.6     (4)    7.7     (4)* 
Don’t know   1.3       (4)   0.8    (2)    3.8     (2) 
Refuse to answer   0.3       (1)   0.0    1.9     (1) 
    
*Significantly different at p<0.05 using a Pearson chi-square test.  
 
4.10 Novel Techniques for Using Medical Marijuana  
The knowledge and use of the novel technique for using marijuana, dabbing, was examined. Overall, 
34.6% (n=126) of participants were aware of dabbing, 53.6% (n=195) were not aware of dabbing, 3.3% 
(n=12) didn’t know, and 8.5% (n=31) refused to answer. Among those who were aware of dabbing 
(n=126), 46.0% (n=58) had ever tried dabbing, 52.4% (n=66) had not ever tried dabbing, and 1.6% (n=2) 
reported that they didn’t know whether they had tried dabbing.  
 
4.11 Cost 
Participants were asked to report the average cost to purchase marijuana and the percentage of the 
cost that was covered. The mean cost of medical marijuana reported by participants was $91.8 
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(SD=87.2) per week and ranged from $1.25 to $500.00 per week. The cost to purchase medical 
marijuana was not at all covered (i.e., 0% coverage) for 85.4% (n=311) of participants, 10.7% (n=39) of 
participants reported limited or partial cost coverage (i.e., 1% - 50%), and 3.9% (n=14) of participants 
reported more comprehensive coverage (i.e., more than 50%).   
 
4.12 Vapourizer Use 
Prevalence of Ever and Current use of a vapourizer use was examined in the survey. Overall, 77.2% 
(n=281) of participants were aware of vapourizing or vaping prior to the study, 11.5% (n=42) of 
participants were not aware of vapourizing or vaping before the study, 3.3% (n=12) of participants 
didn’t know, and 8.0% (n=29) of participants refused to answer. Participants were asked whether they 
had ever used a vapourizer and among those who had ever tried a vapourizer (n=240), 28.3% (n=68) 
used a vapourizer every day during the past 30 days, 18.3% (n=44) used a vapourizer almost every day 
over the past 30 days, 14.2% (n=34) used a vapourizer at least once a week in the past 30 days, 19.2% 
(n=46) used a vapourizer at least once in the last 30 days, and 20.0% (n=48) of participants did not use 
a vapourizer at all in the past 30 days.  
 
A logistic regression model (Appendix D: Table 17) was fitted to examine factors associated with the 
Current use of vapourizers where 1=Current use of a vapourizer (n=165) and 0=no Current use of a 
vapourizer (n=85) (x2= 48.28, p<0.001, Nagelkerke's R2= 0.24). Males (OR=2.46, 95%CI: 1.30-4.76, 
p<0.01), younger age (OR=1.03, 95%CI: 1.00-1.05, p=0.05), white ethnicity (OR=2.52, 95%CI: 1.03-6.19, 
p=0.04), and those with less respiratory symptoms (OR=1.28, 95%CI: 1.05-1.56, p=0.01) reported a 
higher odds of Current use of vapourizers. In addition, significant differences were found between 
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regions (p=0.02): participants from the Prairie Provinces (OR=5.69, 95%CI: 1.50-21.50, p=0.01) and 
from Ontario and Northern regions (OR=5.29, 95%CI: 1.73-16.19, p<0.01) had a higher odds of 
currently using a vapourizer than those from Atlantic Provinces. Education, income, main medical 
reason, and perceived harm of smoking did not significantly differ.  
 
Participants were asked about Ever and Current forms of marijuana used in a vapourizer as well as the 
Ever and Current type of vapourizer used. Table 9 shows patterns of Ever and Current use of 
vapourizers. As Table 9 shows, the most common form of marijuana used in a vapourizer was dried 
herb and the majority of participants used a portable type of vapourizer.  
 
Table 9: Patterns of Vapourizer Use Among Ever (n=240) and Current (n=192) Vapourizer Users 
Characteristic Ever Use Current Use 
   
 % (n) % (n) 
Form of marijuana vapourized   
Dried herb  97.5   (234) 95.8   (184) 
Marijuana resin 19.6     (47) 13.0     (25) 
Butane extract  18.8     (45)  10.9     (21) 
Oil 14.6     (35) 7.3     (14) 
Alcohol extract 1.7       (4) 0.5       (1) 
Carbon dioxide (CO2) extract 1.7       (4)                0.0 
Other 0.8       (2)                0.0 
Don’t know  0.4       (1)                0.0 
Refuse to answer           0.0                0.0 
   
Type of vapourizer used   
Portable vapourizer  72.5  (174) 67.2  (129) 
Stationary vapourizer  59.2  (142) 41.7    (80) 
E-cigarette or vape pen 32.9    (79) 19.3    (37) 
Hand made 0.8      (2)                 0.0 
Other 0.4      (1)                 0.0 
Don’t know  0.8      (2) 0.5      (1) 
Refuse to answer             0.0                 0.0 
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4.13 Perceptions of Vapourizer Use 
Participants who reported Current use of a vapourizer were asked to report their reasons for choosing 
to use a vapourizer. Additionally, participants who were aware of vapourizing, but reported not Ever 
trying a vapourizer were asked to report their main reason for choosing not to use a vapourizer and 
whether they would be willing to use a vapourizer in the future. Table 10 shows participants reported 
reasons and willingness to use a vapourizer.     
 
Table 10:  Reasons, Barriers, and Willingness to Try a Vapourizer 
Characteristic % (n) 
  
Reasons for using a vapourizer  (n=192)  
Less harmful to me than smoking marijuana  79.7 (153) 
It doesn’t smell as much as smoking marijuana  71.4 (137) 
Easy to use  58.9 (113) 
Uses less marijuana  56.8 (109) 
Less harmful to people around me than smoking 51.0 (98) 
Less side effects  40.1 (77) 
Easy to find the correct dose  39.6 (76) 
Provides the best symptom relief  34.4 (66) 
Effects occur faster  27.1 (52) 
Effects last longer  23.4 (45) 
Provides the best high  20.8 (40) 
More affordable  16.7 (32) 
More accessible  15.6 (30) 
Other people I know use a vapourizer too  11.5 (22) 
It’s fun to use  11.5 (22) 
Other  9.4 (18) 
  
Reasons for not using a vapourizer (n=41)  
I’m not interested  26.8 (11) 
Less affordable 19.5 (8) 
Difficult to use  9.8 (4) 
Less accessible  7.3 (3) 
Other  17.1 (7) 
Don’t know  7.3 (3) 
  
Willingness to try a vapourizer in the future (n=41)  
Yes 73.2 (30) 
No 26.8 (11) 
  
 
54 
 
Participants who were aware of vapourization were asked about their perceptions regarding 
acceptability and harm of vapourizing. Table 11 shows participants reported perceptions of 
vapourization.     
 
Table 11: Perceptions of Vapourization among those Aware of Vapourization (n=279) 
Perceptions % (n) 
  
Relative Acceptability of Vapourizers  
Less acceptable than smoking  5.4       (15) 
As acceptable as smoking  27.2      (76) 
More acceptable than smoking  59.1   (165) 
Don’t know 0.4        (1) 
Refuse to answer  7.9      (22) 
  
Harm of Vapourizing   
Not at all harmful 48.0   (134) 
A little or somewhat harmful  38.7   (108) 
Very or Extremely harmful  0.7        (2) 
Don’t know 12.2     (34) 
Refuse 0.4        (1) 
  
Relative Harm of Vapourizing  
Less harmful than smoking 82.8   (231) 
As harmful as smoking  6.5     (18) 
More harmful than smoking  1.1       (3) 
Don’t know 8.9     (25) 
Refuse to answer  0.7       (2) 
  
 
4.14 Sources for Obtaining Medical Marijuana  
Participants were asked which Ever, Main, and Preferred sources they had used for obtaining medical 
marijuana. Table 11 shows prevalence estimates of Ever, Main, and Preferred sources for obtaining 
medical marijuana. The most common Ever, Main, and Preferred source for obtaining medical 
marijuana was through a Health Canada licensed producer. To examine the Main sources for obtaining 
medical marijuana, a logistic regression model (Appendix D: Table 18) was fitted to examine factors 
associated with the Main source for obtaining medical marijuana where 1=Health Canada licensed 
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producer (n=193) and 0=other source (n=53) (x2=19.57, p=0.39, Nagelkerke's R2=0 .12). Participants 
who reported having fewer respiratory symptoms had an increased odds of obtaining medical 
marijuana from a Health Canada licensed producer as their Main source than any other source 
(OR=1.30, 95%CI; 1.05-1.59, p=0.02). No significant differences were found for gender, age, ethnicity, 
education, income, region, main medical reason, and perceived harm of smoking marijuana.  
 
Table 12: Prevalence of Ever, Main, and Preferred Sources for Obtaining Medical Marijuana (N=364) 
Sources Ever Main Preferred 
 %  (n) %  (n) %  (n) 
    
Licensed producer 76.6    (279) 64.6     (235) 43.7    (159) 
Dispensary or club 31.9    (116) 13.5       (49) 16.2      (59)  
Non-licensed source 47.8    (174) 6.0       (22) 3.6      (13) 
Grow it yourself 19.2      (70) 3.8       (14) 23.4     (85) 
Another licenced source 9.6      (35) 3.3       (12) 3.8     (14) 
Other 0.5        (2) 0.3         (1)  1.1       (4)  
Don’t know  1.9        (7) 3.8      (14) 6.0    (22) 
Refuse to answer 7.4      (27) 4.7      (17) 2.2      (8) 
    
 
Participants ranked three sources for obtaining medical marijuana – licensed producer, grow it 
yourself, and non-licensed source- along eight different factors. Figure 2 (and Appendix D: Table 19) 
shows the mean rank comparison of the three sources for obtaining medical marijuana for each of the 
eight factors. Appendix D: Table 20 shows the comparison of Main sources for obtaining medical 
marijuana ANOVA output.  
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Figure 2. Comparison of Ranked Factors for Main Sources for Obtaining Medical Marijuana (N=364)† 
 
†Ranking was completed, where 1 represents the factor ranked as most/high/best, 2 represents moderate/middle, and 3 represents the factor ranked 
least/low/worst (e.g., for the factor cost: 1=most expensive, 2=moderately expensive, and 3=least expensive).    
a,b,c Means with the same letter are significantly different at a p<0.05 tested using an ANOVA. 
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5.0 DISCUSSION 
The current study is among the first to examine patterns of use and perceptions among medical 
marijuana users in Canada after the introduction of the Marihuana for Medical Purposes Regulations 
(MMPR). The findings provide an opportunity to assess changes in the way medical marijuana is 
accessed and used in Canada.  
 
5.1 Medical Reasons for Marijuana Use 
The present study indicates that individuals reporting use of marijuana for medical reasons use it to 
treat a wide range of medical conditions and symptoms, consistent with previous findings12-14,19,24,33,43. 
The MMPR decentralized the process for medical marijuana approval in Canada. Unlike the previous 
regulatory framework, where Health Canada acted as the principal approving body of medical 
marijuana use, physicians now act in this capacity10,44. The new framework (i.e., MMPR) provides 
greater discretion to individual physicians in terms of the medical conditions for which marijuana can 
be prescribed eliminating some of the barriers to accessing medical marijuana that were present 
through the previous regulatory regime. Previously under the MMAR, patients with certain conditions 
were more likely to be approved (e.g., multiple sclerosis and gastrointestinal illness) compared to 
patients with conditions such as anxiety and depression13. Pain was the most commonly reported 
medical condition treated with marijuana in the current study; these findings are consistent with 
national and international research 12-14,19,24,33,43. The current study suggests that the use of medical 
marijuana to mainly treat mental health symptoms may have increased under the MMPR compared to 
during the MMAR (15% vs. 9%)13. 
 
58 
 
Interestingly, approximately 9% of participants in the present study reported not knowing their main 
medical reason for medical marijuana use. It is unclear whether these participants are using marijuana 
to treat multiple conditions and, therefore, could not determine a singular, chief complaint. 
Alternatively, these participants may be using marijuana primarily for recreational purposes and, 
therefore, did not have a main medical reason. It can be difficult to separate medical and recreational 
use of marijuana as the distinction is unclear in some cases, particularly with respect to mental health: 
medical users may benefit from feeling high, which is generally associated with recreational use; on the 
other hand, recreational users may be unaware that they are self-medicating an underlying medical 
condition with marijuana. In the current study, 14% of participants reported using marijuana for both 
health and recreational purposes. Among those who reported using marijuana for both health and 
recreational purposes, on average, one third of their use was recreational. Two previous Canadian 
studies reported that the majority of users had used marijuana recreationally prior to use for approved 
medical reasons; however, there is no other data regarding concurrent recreational use among medical 
users15,43.  
 
5.2 Side Effects of Medical Marijuana Use  
Similar to most medications, marijuana use has secondary effects. The most common secondary effect 
reported by participants in the current study was feeling high, followed by increased appetite and dry 
mouth, which is consistent with previous investigations of medical marijuana15,21,24. In the present 
study, 5% of participants reported feeling no secondary effects resulting from marijuana use. In 
previous work, much higher proportions of participants (e.g., 25% and 71%) reported feeling no 
adverse effects compared to the current study15,20. The variation in reporting effects between studies 
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may be due to various reasons including differences in the wording of the questions or the 
participants’ perceptions of the questions asked. The current study asked participants to report the 
effects experienced resulting from marijuana use without any indication whether the effects were 
negative or positive, whereas past research explicitly asked participants to report adverse effects. 
Whether certain secondary effects resulting from marijuana use are negative or positive may be 
subjective and may depend on the context. For example, AIDS patients would associate increased 
appetite as a positive effect since AIDS patients lose weight at a relatively fast rate, whereas a patient 
with another condition may associate an increased appetite as a negative effect. The prevalence of any 
serious secondary effects was low (e.g., 6% paranoia and hallucinations), consistent with past 
research15,20. However, it is likely that there is a sample bias given that users who have experienced 
serious side effects are unlikely to continue using medical marijuana and would not have been eligible 
for the survey.  
 
5.3 Patterns of Medical Marijuana Use 
The majority of participants reported frequent, long-term, daily use of marijuana, with little indication 
that patterns of use have changed since the MMPR came into effect12,13,19,24,33,38. However, daily use of 
marijuana for medical purposes was less common in the current study compared to two previous 
Canadian studies (56% vs. 83% and 94%)38,43. In addition, patterns of use reported in the current study 
were similar to international studies12,19,24,59 with the exception that daily use was less common in the 
current study compared to a study conducted in the US in 2007 (56% vs. 90%, respectively)59. Overall, 
patterns of use seem to have remained stable over time and internationally among medical marijuana 
users.   
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One study comparing the medical use of marijuana to recreational use found that medical use tends to 
be more frequent and for longer periods of time and recreational users reported using marijuana 
rarely15. Alternatively, the current study examined recreational use of marijuana among those who 
were medical users and found similar frequencies of use for only medical users compared to medical 
users who also use marijuana recreationally. Thus, there may be some differences in patterns of 
marijuana use; however, again, it is difficult to separate medical and recreational use of marijuana.   
 
Most participants reported never mixing their marijuana with tobacco (~70%) while 23% reported 
some level of mixing. Similar findings for mixing tobacco with marijuana were reported by HIV/AIDS 
patients in a Canadian study conducted in 200738; however, a Canadian study conducted in 2003 in 
Nova Scotia with pain patients reported much higher estimates (~47%) of mixing than the current 
study15. Mixing tobacco with marijuana is generally more common in Europe than in North 
America12,24,43. Additionally, there is evidence to suggest that mixing tobacco with marijuana can have 
implications on the physiological effects of marijuana24. One study found that mixing tobacco with 
marijuana may release more THC from marijuana when smoked; thus, some medical users may benefit 
from mixing marijuana with tobacco in terms of symptom relief72.  
 
5.4 Prevalence of Modes of Delivery 
The current findings suggest a possible shift in the popularity of modes of delivery from smoking to 
alternative modes. Although smoking a joint was the mode of delivery most commonly tried, 
approximately two thirds of participants reported trying a vapourizer and eating marijuana in foods. 
Contrary to our hypothesis, using a vapourizer was the most common mode of delivery currently used 
61 
 
and it was the most preferred by participants compared to smoking a joint and eating in foods. Overall, 
more participants reported current use of alternative modes and preferred alternative modes 
compared to smoking. It is interesting that alternative modes of delivery were more popular than 
smoking even though the MMPR restricts the use and sale of medical marijuana to only dried herb, 
which is most easily smoked.  
 
Results from the present study demonstrate that the use of alternative modes of delivery is increasing. 
Previous studies have all found that smoking is the most commonly used and most preferred mode, in 
contrast to the current findings12,15,17,19,33,38,43. Among past studies that examined vapourizer use, the 
prevalence of using a vapourizer was generally low, falling between 8% and 20%12,33,38. Alternatively, 
one Canadian study conducted in 2007 found that 52% used a vapourizer, which is a similar estimate to 
the current study; however, that same study reported a higher proportion of participants smoked 
(88%) and ate (72%) their medical marijuana compared to vapourizing43. Inconsistent with the current 
results, other Canadian studies also reported that eating in foods was the second most commonly used 
mode of delivery, even more common than using a vapourizer12,33,38,43. Although medical marijuana 
users reported trying and concurrently using multiple modes of delivery, vapourizing was the most 
popular mode of delivery used, more so than smoking a joint. Overall, the findings indicate a 
substantial increase in the use of vapourizers among approved medical marijuana users.  
 
More than one quarter of participants that were aware of vapourizers used a vapourizer every day 
during the past 30 days. Although past research regarding frequency of using a vapourizer is limited, an 
international study that included Canadians also found that participants reported using a vapourizer 
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daily24. The popularity of vapourizers for using marijuana may have been influenced by the recent 
increase in awareness and use of electronic cigarettes, which vapourize nicotine73. Most of the 
participants who used a vapourizer reported using a portable type of vapourizer, which is similar to an 
e-cigarette. The present findings are inconsistent with the type of vapourizer reported by two previous 
studies that found the type of vapourizer most commonly used was the Volcano, a non-portable 
vapourizer24,60. The findings suggest that e-cigarettes may have revitalized vapourizing technology with 
respect to the marijuana market. 
 
Using a vapourizer instead of smoking marijuana could prevent some of the negative respiratory health 
consequences associated with smoking. Findings from the current study adds to previous literature by 
showing current use of alternative modes of delivery and current use of a vapourizer were both 
associated with fewer respiratory symptoms26,55,56. A previous study exclusively examined vapourizing 
and found that participants using a vapourizer had significantly less respiratory symptoms compared to 
smoking26. Overall, the majority of participants in the current study reported having at least one or 
more respiratory symptoms (e.g., cough, phlegm, shortness of breath, etc.) and approximately 14% of 
participants reported having a respiratory illness (e.g., asthma, COPD, lung cancer). Participants in the 
current study had a higher prevalence of respiratory illness than the general Canadian population (14% 
vs. 9%)74. However, the direction of this association is unclear from the current study’s data: individuals 
with respiratory illnesses or respiratory symptoms from other conditions may be more likely to use 
marijuana, or chronic smoke inhalation from marijuana could cause or exacerbate respiratory 
symptoms.  
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The present study found that current use of alternative modes was associated with a greater 
perception of harm from smoking and with being more highly educated. Possibly, these populations of 
users are also more aware of ways to reduce the negative health risks of marijuana use and have the 
resources available to do so. Participants most commonly perceived a moderate harm from smoking 
marijuana; however, just over one fifth of participants perceived smoking marijuana as not at all 
harmful. Although the majority of participants understood that smoking marijuana may result in some 
negative health consequences, the results demonstrate that there were some participants who did not 
perceive smoking marijuana as harmful at all. Asking participants their perceptions of harm from 
smoking is complicated as attitudes toward smoking marijuana can depend on the context and in 
which ways it is used68. For example, participants in the current study who use marijuana only for 
medical reasons may perceive no harm from smoking marijuana because they gain medical benefits, 
but may perceive regular recreational smoking of marijuana as very harmful. In addition, previous 
research states that concerns surrounding smoking marijuana are mainly due to the substance’s illegal 
status and to a lesser extent, the negative health effects12,68. Most of the participants in the current 
study seem to be aware of possible negative health implications resulting from smoking marijuana.  
 
5.6 Perceptions and Personal Importance of Factors by Modes of Delivery 
The way in which medical marijuana users perceive the modes of delivery has implications for which 
modes they use. Participants perceived smoking and vapourizing as fairly similar on the 12 factors. 
However, smoking was reported to be perceived as having the highest level of harm and vapourizing 
having the least side effects. The findings suggest that most medical marijuana users that report using 
a vapourizer do so because they are aware and understand that using a vapourizer can reduce negative 
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health consequences that are associated with smoking. More than 80% of participants reported that 
vapourizing is less harmful than smoking and almost half of the participants said vapourizing is not at 
all harmful. The perception among medical marijuana users that vapourizers are a more acceptable 
mode of delivery with a lower risk of harm compared to smoking is most likely the reason for its 
popularity. General concerns about smoking-related health consequences were also noted by 
participants in previous research12,24. The perceptions and concerns among medical marijuana users 
surrounding the harm from smoking is warranted based on many previous research findings23-27. 
Health Canada also recommends that medical marijuana users can vapourize as an alternative to 
smoking marijuana for some health advantages3. Currently, it is unclear to what extent vapourizers are 
being recommended to approved medical users by physicians, health authorities, and licensed 
producers due to a gap in the existing knowledge base. 
 
Another reason participants reported that they use a vapourizer was that vapourizing doesn’t smell as 
much as smoking marijuana. Because using a vapourizer doesn’t smell, it may be less obvious to other 
people that marijuana is being used, which may reduce possible associated social stigma. Different 
international jurisdictions, such as Australia and the US, have reported similar reasons for vapourizing 
citing efficacy, reliability, and safety reasons as well as preferences in taste, smell, perceived effect, and 
perceived health benefits12,60.  
 
The study identified additional factors that may determine choice of mode of delivery. First, smoking 
was perceived to have the fastest time to onset of effect followed by vapourizing with the second 
fastest time to onset. However, past scientific data reported using a vapourizer and smoking obtained 
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the same blood cannabinoid concentration levels at the same time53. After assessing the scientific 
literature available, Health Canada stated that absorption may even occur somewhat faster with a 
vapourizer compared to smoking3. Thus, the sample of medical marijuana users in the present study 
have different perceptions of the time to onset of effect compared to biological outcomes.  
 
Second, it was not surprising that smoking was perceived to be the most accessible mode of delivery. 
Due to the MMPR in Canada, dried herb was the only form available at the time the survey was 
conducted, and it is easiest to smoke dried herb, thus making smoking more accessible to medical 
users. Interestingly, although smoking was perceived to be the most accessible mode of delivery, the 
most common mode used was a vapourizer suggesting that accessibility was not a large enough barrier 
to prevent approved medical marijuana users from using a vapourizer. To our knowledge, there has 
been no other research that examined accessibility of modes of delivery to compare the current results 
with.  
 
Eating marijuana in foods was the mode perceived to have the least desired effects compared to both 
smoking and using a vapourizer, including the slowest time to onset of effect, worst high, most stigma, 
hardest to find correct dose, hardest to use, and least accessible. However, eating in foods was 
perceived to have the longest duration of effect, consistent with the evidence that oral administration 
of marijuana results in a longer duration of effects3,24,59. The longer lasting effect from eating can 
reduce the need for frequent dosing; however, longer durations can also be unfavourable if the user 
overdoses and prolongs the undesired effect24,59. Additionally, pre-made edibles could not be legally 
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purchased in Canada under the MMPR at the time the study was conducted, meaning edibles had to 
be baked by hand. Baking edibles takes greater effort and time to prepare compared to other modes.  
 
In addition to asking participants their perceptions about the modes of delivery, we asked which 
factors were important when selecting which modes of delivery to use. The importance placed on each 
of the 12 perceived factors has implications for which modes of delivery medical marijuana users select 
to use. Symptom relief was rated as the most important factor when deciding which mode of delivery 
to use suggesting that approved medical users would use the mode that relieves their symptoms the 
best. However, participants’ perceptions of the modes didn’t differ on symptom relief indicating that 
each mode of delivery – smoking, using a vapourizer, and eating in foods – provides similar relief of 
symptoms. Therefore, medical marijuana users may select any mode of delivery to relieve their 
symptoms.  
 
Participants rated cost as the second most important factor when selecting which mode of delivery to 
use, indicating that medical marijuana users would prefer to use an inexpensive mode. Eating in foods 
and using a vapourizer were both perceived as the most expensive modes and smoking was perceived 
as the least expensive mode. It is interesting that using a vapourizer was the most popular mode of 
delivery used even though it was perceived as expensive and cost was rated as the second most 
important factor when selecting which mode to use. Furthermore, the most common reasons for not 
trying a vapourizer were ‘not interested’, followed by ‘not affordable’. Previous studies have also cited 
cost as a reason for not using a vapourizer60,75. For example, one study reported a mean cost of 
approximately $250 to purchase a vapourizer60. Cost may be important to medical marijuana users as 
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cost coverage for medical marijuana use in general is low in Canada76. Additionally, most users are 
chronically ill and, therefore, rely on disability or unemployment income, generally placing them in a 
low socioeconomic stratum. Using a vapourizer may not be an option for medical users who have a low 
income and cannot afford it. Although, medical users still seem to be interested in using a vapourizer 
as three quarters of the participants who had not tried a vapourizer reported that they would be 
willing to try a vapourizer in the future. Overall, these findings indicate that cost and accessibility may 
be the largest perceived barriers to using a vapourizer; however, most approved medical marijuana 
users continue to use and want to use a vapourizer.  
 
5.7 Forms of Marijuana  
During the study period under the MMPR, approved medical users could only receive dried medical 
marijuana from a licensed producer within the legal limits44. Therefore, not surprisingly, dried herb was 
the most prevalent form of marijuana tried and currently being used, which is in agreement with our 
hypothesis. Participants most commonly reported that a reason for using dried herb was that dried 
herb was significantly more accessible than alternative forms. Therefore, approved medical marijuana 
users seem to be using dried herb mainly due to its ready accessibility. A 2001 Canadian survey among 
pain patients using medical marijuana examined dried herb and oil forms of marijuana and also found 
that dried herb was the form most commonly used even before the MMPR was introduced15. The use 
of marijuana for medical purposes was established in Canada in 2001 indicating that since the 
introduction of Canadian medical marijuana laws, dried herb has been the most popular form of 
medical marijuana. However, it is interesting to note that participants from the current study were 
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trying and using multiple forms of marijuana, including oil and extracts, even though alternative forms 
were illegal to use at the time.  
 
However, as of June 11, 2015, immediately after the survey was completed, medical use of alternative 
forms of marijuana became legal as a result of a court decision made against the federal government. 
On July 8, 2015, Health Canada announced that alternative forms of medical marijuana can legally be 
produced and sold by licensed producers47. Health Canada revised the medical marijuana regulation 
expanding the legal forms of marijuana to oil, buds, and leaves in addition to dried marijuana47. The 
findings from the current study support media coverage stating that approved medical marijuana users 
supported this change in regulation: over three quarters of participants reported that they would use 
extracts if they were available. Additionally, participants reported that alternative forms of marijuana 
had effects that last significantly longer, have significantly less side effects, had significantly higher 
quality, and were significantly less harmful than dried herb.  
 
Alternative forms of marijuana, such as oils and extracts, generally have higher concentrations of 
cannabinoids, which may have implications for how long effects last and dosing intervals. However, 
opponents are worried about an increase in the use of highly concentrated extracts leading to an 
increase in overdoses48. Additionally, alternative forms of marijuana allow the use of alternative modes 
of delivery, such as oral administration and some types of vapourizers, which have a lower risk for 
negative health consequences in comparison to smoking. Allowing the use of alternative forms and 
thus, alternative modes of delivery, may result in reduced respiratory illness and symptoms among 
approved medical marijuana users. The current study found that participants were more likely to use 
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alternative forms of marijuana if they perceived the harm from smoking as high. Those who believe 
smoking is harmful to their health may be more likely to use alternative forms in alternative modes 
instead of smoking dried herb. To date, no other research has examined reasons for choosing forms of 
marijuana. With the predicted increase in the use of alternative forms of marijuana resulting from the 
revision to regulation, future research should continue to monitor trends regarding the use of 
alternative forms of marijuana.  
 
5.8 Novel Techniques for Using Medical Marijuana 
Dabbing is a novel technique used for administering marijuana and anecdotal evidence suggests that it 
is a fairly popular technique used by medical marijuana users. It is important to note that little research 
has assessed dabbing; therefore, benefits and harms of the technique are not well known. The current 
study found that approximately 35% of participants were aware of dabbing and of those, nearly half 
had tried dabbing. The findings provide evidence that dabbing is relatively well-known. The use of 
dabbing may increase in popularity as a result of the revised regulation allowing alternative forms of 
marijuana to be used, such as extracts, which are required for dabbing. Only one other study 
conducted by Loflin in the US examined dabbing and reported that the most common reasons for 
preferring dabbing were that it requires fewer intakes for an effect, the effect is stronger, and the 
“high” better48. Dabbing may have implications for symptom relief and dosing as users may not need 
to use marijuana as often with better symptom relief. The current study is the only data available that 
reports prevalence estimates of dabbing, therefore, future research should examine the use of dabbing 
and further investigate reasons for dabbing as well as benefits and harms of the technique.  
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5.9 Cost 
Currently, in Canada, the government does not cover the cost of medical marijuana with the exception 
of veterans. There is one case where a student, Jonathan Zaid, with assistance from Bedrocan, 
successfully requested the addition of medical marijuana to the existing list of medications and 
associated therapies covered by the University of Waterloo’s student insurance plan76. However, other 
approved medical marijuana users very rarely receive any coverage of medical marijuana costs through 
health insurance in Canada76. Previous research states that medical users have trouble affording 
medical marijuana and some people even stop taking medical marijuana because they cannot afford to 
take it12,43. The current study found that the mean cost participants spent on medical marijuana was 
nearly $100 per week. The majority of participants had no coverage at all and only about 4% of 
participants had over 50% of the cost covered. The cost of medical marijuana was estimated in a 
Canadian study from 2007 as approximately $60 per week, which is a lower estimate than the current 
study38. The estimates of cost may differ as the current study was conducted 7 years later with a 
different medical marijuana regulation (i.e., MMPR) in place. Under the MMPR, marijuana can only be 
purchased from one source, licensed producers, potentially influencing an increase in the price to 
purchase medical marijuana.  
 
5.10 Sources for Obtaining Medical Marijuana  
Approved Canadian medical marijuana users could only legally access marijuana from licensed 
producers at the time of the survey’s completion due to MMPR restrictions. The MMPR restriction may 
have influenced how medical marijuana users obtain marijuana resulting in a shift toward licensed 
producers. Participants in the current study reported that the most often used, and preferred, source 
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for obtaining medical marijuana was through licensed producers. Licensed producers and non-licensed 
sources were ranked as the most accessible; however unlike the latter, licensed producers were 
reported to be the safest, provided the most potent marijuana, provided the best symptom relief, and 
was the least stigmatizing source. Licensed producers were ranked as a favourable source for obtaining 
medical marijuana by this sample of approved users. The current sample was recruited through 
licensed producers, therefore, satisfaction with licensed producers may be over-represented as those 
using other sources may have negative opinions about licensed producers and may have been 
excluded from completing the survey. 
 
Assuming no selection bias in our study population, the findings indicate a possible change in trends 
and perceptions regarding sources used for obtaining medical marijuana. Earlier studies showed that 
medical marijuana users commonly obtained marijuana from friends and family, dispensaries or clubs, 
and growing it themselves and obtaining marijuana from a licensed producer was the least common 
source24,38. Furthermore, past research states that medical marijuana users (both approved and non-
approved) were not satisfied with licensed producers due to concerns regarding the safety and quality 
of the marijuana produced38. From the results found in the current study, it seems as though medical 
marijuana users were more satisfied with licensed producers through the MMPR than previously, 
through the MMAR. The change in regulation led to increases in the number of licensed producers as 
previously, under the MMAR, there was only one licensed producer for Health Canada. The most 
recent count of approved licensed producers in Canada is now at 2544. Possibly, the increase in number 
of licensed producers serving approved medical marijuana users’ needs has increased accessibility as 
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well as product options (i.e., competition between multiple companies may be beneficial for medical 
marijuana users).  
 
The current study examined whether specific characteristics were associated with mainly using 
licensed producers as the source for obtaining medical marijuana. Participants who reported less 
respiratory symptoms were more likely to obtain medical marijuana from licensed producers than from 
any other source. It may be that users obtaining marijuana through licensed producers have been 
exposed to more paperwork and websites containing health information regarding medical marijuana 
and thus, were more likely to partake in harm reduction strategies that reduce respiratory symptoms. 
However, there is currently no evidence to support this finding.   
 
The current study also indicates alternative sources, other than licensed producers, have previously 
been used and continue to be used even though licensed producers are the only legal source for 
obtaining medical marijuana. Some of the participants preferred to grow their own marijuana (23%) or 
use dispensaries or clubs (16%); however, overall, participants ranked growing marijuana and using 
non-licensed sources as less favourable than using a licensed producer. Participants ranked growing 
marijuana as the source that takes most amount of time and was the least accessible and was ranked 
in the middle for safety, symptom relief, and level of stigma. Non-licensed sources (i.e., dispensaries or 
clubs) were ranked by participants as the most accessible (tied with licensed producers), took the least 
amount of time to receive, least safe, worst symptom relief, and the most stigmatizing.  
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Evidence from a previous Canadian study also found that medical marijuana users perceived 
disadvantages for growing their own marijuana and using non-licensed sources38. This previous study 
reported concerns from medical users regarding growing their own marijuana, such as its illegality, 
possible crop failure, and it requires a lot of work38. Consistent with past research, the most negative 
perceptions were associated with non-licensed sources. Concerns about safety, quality, availability, 
and stress regarding illegality were mentioned in the previous study38. Thus, there are drawbacks to 
using alternative sources for obtaining marijuana and the current study suggests that medical users 
want a legal, regulated system, such as licensed producers, to access marijuana. 
 
Although this study shows that most approved medical users preferred using licensed producers, there 
is an ongoing court case challenging the right that medical marijuana users should be able to obtain 
marijuana from other sources in addition to licensed producers. In fact, Vancouver just recently 
approved a licensing system allowing medical marijuana dispensaries and clubs to remain open against 
the federal government’s regulations77. The new system includes an annual licensing fee of $30,000 
and a restriction of 300 metres from schools, community centres, and other dispensaries or clubs77. 
There are already approximately 100 dispensaries and clubs in Vancouver and this number is expected 
to increase with the new system77. It is also expected that an increase in medical marijuana users 
obtaining marijuana from dispensaries and clubs will result. It is important to note that this new 
system for allowing dispensaries and clubs in Vancouver does not include the requirement of safety 
standards and is not supported by Health Canada77. Participants in the current study preferred a 
regulated system to ensure quality and safety of the marijuana. Additionally, opponents argue that 
allowing dispensaries and clubs will result in more children having access to marijuana77. Although 
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unlikely, if dispensaries became legal all over Canada, a change in where the majority of approved 
medical marijuana users obtain marijuana from might occur. In the meantime, approved medical users 
appear to be satisfied with obtaining marijuana from licensed producers.   
 
5.11 Strengths and Limitations 
The current study has a number of strengths and limitations. First, a convenience sample was recruited 
through licensed producers as probability sampling was not feasible. Therefore, approved medical 
marijuana users who were not registered with one of the licensed producers who assisted with 
recruitment may not have been included in the survey, though there is no reason to believe the 
approved users from other licensed producers not included in the current sample would differ from 
those included. Approved medical marijuana users who were not registered with a licensed producer 
at all may have also been excluded from taking part in the survey, which may have inflated the 
prevalence of using licensed producers as the source for obtaining marijuana. Those who use 
marijuana for health reasons, but were not approved were not eligible to complete the survey; 
however, there was no way to validate that each participant was in fact approved. A large proportion 
of Canadians report using medical marijuana, but are not approved, therefore, this sub-population of 
users were not included in the results34. To our knowledge, information regarding differences between 
non-approved and approved medical users is not available, thus possible implications from excluding 
this sub-population from the sample are unclear. Individuals without internet access could not 
complete the survey; however, as of 2012, 83% of Canadians aged 16 or over had internet access for 
personal use, thus only a small proportion would be excluded on that basis78. Participants were given 
$10 as a thank you, which typically improves response rates among lower income groups. It is unclear 
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how many people were reached through email and, therefore, a response rate calculation was not 
possible. However, approximately 79.4% of interested participants attempted the survey.  
 
Comparing the current study to estimates of the general population who use marijuana shows that 
approved medical users may be similar on some characteristics. For example, the use of marijuana 
tends to be more prevalent among males compared to females in both the general public and among 
approved medical users34. However, the use of marijuana in general appears to be higher among youth 
than that of adults, which differs from the current study as youth were not included in the study34. 
Additionally, it would be expected that the prevalence of marijuana use among approved medical 
users may consist of a different age group compared to marijuana use in the general population as 
older adults are possibly more likely to be ill. Additionally, in 2013, under the MMAR, Health Canada 
released information showing that the majority of Canadians with medical marijuana approval resided 
in British Columbia, accounting for nearly half of all licensed medical users in Canada, followed by 
Ontario at about 30%37. Therefore, the current sample may have potentially under represented British 
Columbia residents and over represented Ontario residents. The current study revealed similar 
patterns of marijuana use compared to past studies including reporting amount, frequencies, and 
reasons for use12-14,19,24,33,38,43. However, currently, there is no way to know how representative the 
present study’s sample is of the entire population of approved Canadian medical marijuana users since 
demographic information of approved users is not available. 
 
76 
 
Second, the survey was cross-sectional; thus, a temporal order could not be established. For example, 
results from the survey could not conclude whether using a vapourizer results in reduced respiratory 
symptoms or whether those with less respiratory symptoms use a vapourizer.   
 
Third, the survey relied on self-report, which may contribute to a social desirability bias where 
participants do not answer truthfully and instead answer how they believe others in society would 
want them to answer. For example, social desirability may have led to the under representation of 
recreational use of marijuana. To address this limitation, participants were assured that their 
responses were strictly confidentiality given the sensitivity of the types of questions asked. In addition, 
online surveys are typically subject to lower levels of social desirability bias compared to face-to-face 
surveys, given the greater anonymity79. 
 
Strengths of the study included a systematic recruitment of a large sample of approved medical 
marijuana users from across Canada. This is one of the first studies to exclusively examine approved 
Canadian medical marijuana users, which is important as this is the population most directly impacted 
by changes to medical marijuana regulation. The timeliness of the data was also a major strength as it 
was important to assess the possible implications of the MMPR, which to our knowledge had not been 
examined until the current study. Additionally, the survey was pre-tested using cognitive interviewing 
to ensure that the questions asked were phrased in a way that participants would clearly know what 
was being asked70. Cognitive interviewing helps to legitimize that the results from this study are 
accurate70. Lastly, a wide range of outcomes were examined, which included some measures that have 
77 
 
not been studied previously (e.g., personal importance of factors by mode of delivery). Overall, the 
current study adds important knowledge to the existing medical marijuana research available.  
 
5.12 Conclusions 
This study presents a general picture of the current state of medical marijuana use among approved 
users in Canada. The findings indicated that approved users have tried multiple modes of delivery, but 
using a vapourizer was the most commonly used and most preferred mode. Vapourizers have the 
potential to substitute smoking and thus, reduce negative health impacts associated with smoking 
marijuana. To increase the use of vapourizers among approved medical users even further, the current 
study’s findings suggest that vapourizers need to be more accessible and less expensive. Additionally, 
the study found that alternative forms of marijuana were favoured; however, dried herb was used 
more often due to its easy accessibility within the MMPR. Accessibility of alternative forms may no 
longer be a barrier to use as a revision to the regulation is now allowing licensed producers to produce 
and sell alternative forms of marijuana. Monitoring forms of marijuana being used by medical users as 
well as tracking possible overdoses may be beneficial as alternative forms generally have higher 
concentrations of cannabinoids. A Quebec Cannabis registry has been created in order to track patient 
use information as well as monitor patient safety and will result in a database of useful information for 
researchers80. This type of registry would be useful for monitoring the implications resulting from 
ongoing regulation changes for medical marijuana use in Canada. However, the current study is the 
most recent data examining prevalence, patterns of use, and reported perceptions among approved 
medical marijuana users in Canada. Therefore, this study could be useful for informing current and 
future medical marijuana policies that are continuously being revised and adapted.  
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Future studies in the area of approved medical marijuana research could consider the length of time it 
takes to contact and arrange recruitment with licensed producers. This is a highly motivated 
population, thus, qualitative methods for research could be done fairly easily in order to capture more 
information from approved medical users. Additionally, while respecting confidentiality and anonymity 
a way to validate participants’ approval to use medical marijuana would have been beneficial for 
strengthening the methodological rigour of the current study. Suggestions for future areas of interest 
include examining perceptions of the modes of delivery that participants had used before compared to 
their perceptions of all modes as this may have influenced which modes they select to use as well as 
differences in prevalence of modes by licensed producer as licensed producers may be providing 
different information regarding modes of delivery to their clients.  
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APPENDIX A 
Cognitive interviewing protocol 
 
INTRODUCTION 
“In the questions that follow, we want to find out more about what you think about marijuana.  We are 
NOT interested in finding out if you are correct or incorrect.  We want to make sure that we are asking 
the questions in ways that you and other people clearly understand.  Sometimes, it will seem like we 
are asking the same question over and over again.  Please be patient with us.  We do not doubt what 
you tell us.  We just need to double-check that the questions are working like we think they are. 
For some of the questions, I will ask you how you arrived at your answer.  Again, this is not because we 
do not believe you.  It will be like my asking you to tell me how many windows you have in your house 
by closing your eyes, visualizing your house, and your telling me how you go from room to room of your 
house in order to count the windows there.  As an exercise, let’s try that now.  Please close your eyes, 
and tell me how many windows are in your house, by taking me from room to room.”   
[response] 
“Thanks.  Now, when we ask you a question and give you some possible responses from which to 
choose your response, I would like you to do the same thing.  You can tell me your understanding of 
the question and take me through your thoughts as you decide on the response that is best for you.” 
[NOTE: The interviewer will use a semi-structured interview protocol, using the following types of 
probes, as appropriate to the questionnaire items and interview responses.] 
 
ISSUES THAT CAUSE RESPONSE ERROR & EXAMPLE COGNITIVE PROBES 
1. INSTRUCTIONS:  Look for problems with any introductions, instructions, or explanations from the 
respondents’ point of view 
 COMPLICATED, CONFLICTING OR INACCURATE instructions, introductions, or explanations 
 EX. PROBE:  At the end of a long intro, but before the question itself:  Before I get to the actual 
question, tell me what this introduction is telling you. 
2.  CLARITY:  Identify problems related to communicating the intent or meaning of the question to the 
respondent. 
 WORDING:  question is lengthy, awkward, ungrammatical, or contains complicated syntax 
 EX. PROBE:  Can you tell me in your own words what that question was asking? 
 
 TECHNICAL TERMS are undefined, unclear, or complex 
 EX. PROBE:  What does the word [term] mean to you as it’s used in this question? 
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 VAGUE:  there are multiple ways to interpret the question or to decide what is to be included or 
excluded 
 EX. PROBE:  Tell me what you were thinking when I asked you about [topic] 
 
 REFERENCE PERIODS:  are missing, not well specified, or in conflict 
 EX. PROBE:  1) Can you remember what time period this question is asking about?  OR 2) You said 
[answer].  What time period does that cover? 
3. ASSUMPTIONS:  Determine whether there are problems with assumptions made or the underlying 
logic. 
 INAPPROPRIATE ASSUMPTIONS are made about the respondent or about his/her living situation. 
 EX. PROBE: 1) How well does that question apply to you? OR 2) Can you tell me more about that? 
 
 ASSUMES CONSTANT BEHAVIOR or experience for situations that vary 
 EX. PROBE:  Would you say that mostly stays the same or does it vary or depend? 
 
 DOUBLE-BARRELED:  Contains more than one implicit question 
 EX. PROBE:  Tell me more about your opinions on that. 
4. KNOWLEDGE/MEMORY:  Check whether respondents are likely to or not know or have trouble 
remembering information 
 KNOWLEDGE MAY NOT EXIST:  respondent is unlikely to know the answer to a factual question. 
 EX. PROBE:  How much would you say you know about [topic]? 
 
 ATTITUDE MAY NOT EXIST:  Respondent is unlikely to have formed an attitudes being asked 
about 
 EX. PROBE:  How much thought would you say you’ve given to this? 
 
 RECALL FAILURE:  Respondent may not remember the information asked for 
 EX. PROBE:  1) How easy or difficult is it to remember [topic]? OR 2) You said [answer].  How sure 
are you of that? 
 
 COMPUTATION PROBLEM:  The question requires a difficult mental calculation 
 EX. PROBE:  How did you come up with that answer? 
5. SENSITIVITY/BIAS:  Assess questions for sensitive nature or wording and for bias 
 SENSITIVE CONTENT (GENERAL):  the question asks about a topic that is embarrassing, very 
private, or that involves illegal behavior 
 EX. PROBE:  1) Is it okay to talk about this in a survey, or is it uncomfortable? OR 2) In general, 
how do you feel about this question? 
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 SENSITIVE WORDING (SPECIFIC):  given that the general topic is sensitive, the wording  
 EX. PROBE:  The question uses the word [term].  Does that sound okay to you, or would you 
choose something different?  
 
 SOCIALLY ACCEPTABLE:  a socially desirable response is implied by the question 
 EX. PROBE:  1) How did you come up with that answer?  OR 2) Do all the possible answers seem 
okay, or did it seem like there’s one that’s supposed to be the right answer? 
6. RESPONSE CATEGORIES:  Assess the adequacy of the range of options 
 OPEN-ENDED QUESTION:  Is inappropriate or difficult to answer without categories to guide 
 EX. PROBE:  Was it easy or difficult to decide what answer to give? 
 
 MISMATCH:  question does not match response categories 
 EX. PROBE:  1) How easy or hard was it to find your answer on that list?  OR 2) You said [answer].  
How well does that apply to you? 
 
 TECHNICAL TERMS:  are undefined, unclear, or complex 
 EX. PROBE:  In this list, what does [term] mean to you? 
 
 VAGUE:  responses categories are subject to multiple interpretations 
 EX. PROBE:  Tell me what you were thinking when I asked about [topic]? 
 
 OVERLAPPING:  categories are not mutually exclusive 
 EX. PROBE: 1) How easy or hard was it to find your answer?  OR 2) Tell me why you chose 
[answer] instead of some other answer on the list. 
 
 MISSING:  some eligible responses are not included 
 EX. PROBE:  How easy or hard was it to choose an answer? 
 
 ILLOGICAL ORDER:  order not intuitive 
 EX. PROBE:  How was it for you to go through that list?  Did that cause any difficulties? 
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INTERVIEW INFORMATION 
 
 
ID#  
ENTER DATE (dd/mm/yy)    |___|___|/ |___|___|/ |___|___| 
RECORD SEX AS OBSERVED  Female1  
 Male2 
A.  How old are you now? 
 
ENTER NUMBER      
                                   |_____|_____| 
B.  What is the highest level of formal 
education that you have completed?  
 Elementary1 
 Middle school completed2  
 Technical school or High School (completed) 3  
 University (incomplete)4 
 University degree (complete)5 
 Post-graduate6 
 Other7 (specify)______________________________ 
Start time:   
End time:   
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QUESTIONNAIRE ITEMS TO BE TESTED 
 
[NOTE: The following questionnaire items are the ones that will be evaluated using the kinds of probes 
above. In some cases, specific probes have been suggested below.] 
 
Introduction  
 
The following questions are about your use of marijuana. 
 
When we use the term marijuana, we mean marijuana in any form including hashish, hash oil, 
synthetics, or other marijuana derivatives (e.g., edibles, extracts).  
 
Also, when we use the phrase ‘marijuana for health reasons’, we mean the use of marijuana for 
relief of health symptoms, also known as “medical marijuana”.  
 
 Probe: Before I get to the actual question, tell me what this introduction is telling you. 
o Can you explain in your own words what ‘marijuana for health reasons’ means? 
 
 
Eligibility  
 
Are you CURRENTLY approved for an “Authorization to Possess Marihuana for Medical Purposes” in 
Canada? (select only one) 
1. Yes 
2. No 
3. Don’t know 
4. Refuse to answer 
Note: only eligible if answer is yes [1] 
 
 Probe: What does the word approved mean to you as it’s used in this question? 
 
 
Marijuana Behaviours  
 
In the PAST 30 DAYS, on average, on how many of these days did you use marijuana (for any 
reason)?  
(if you refuse to answer this question, please enter 00) 
 
_____ [00-30 limit]   
 
 
 Probe: Was it easy or difficult to decide what answer to give?  
 
 
ONLY IF REC USER AS WELL:  
Approximately, how much of your marijuana use is recreational (i.e., to get high, to be social)? 
1. 0% - I only use marijuana for health reasons 
2. 25%  
3. 50% 
4. 75% 
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5. 100% - I only use marijuana for recreation reasons 
6. Don’t know 
Refuse to answer 
 
 Probe: How did you come up with that answer? 
 
You selected more than one way of using marijuana in the past 30 days.  
We would like to know how much marijuana you use each way. 
Please enter the percentage of use for each in the boxes below (e.g. 50% smoking a joint, 50% eating 
in foods or baked goods). 
 
_________ (numerical: 0-100 and show %)  
 
 Probe: How did you come up with that answer? Was it easy or difficult to decide what answer to 
give? 
 
 
Perception of Modes 
 
The next questions ask about three ways of using marijuana in more detail: smoking marijuana, using a 
vapourizer, and eating marijuana in foods.  
 
Compared to other ways of using marijuana, please rate [SMOKING/ USING A VAPOURIZER/ 
EATING IN FOODS] on the following factors:  
 
 1 
Very short  
2 3 4 5 
Very long 
Don’t know 
Duration of effect (i.e., how long 
it lasts) 
□ □ □ □ □ □ 
 
 1 
Very slow  
2 3 4 5 
Very quick 
Don’t know 
Time to onset of effect (i.e., 
how quickly the effects occur) 
      
 
 1 
Very low  
2 3 4 5 
Very high 
Don’t know 
The amount of marijuana 
needed for effect 
      
 
 1 2 3 4 5 
Very easy 
Don’t know 
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Very 
difficult  
Ease of use       
 
 1 
Very 
difficult  
2 3 4 5 
Very easy 
Don’t know 
Ability to find correct dose        
 
 1 
Very bad  
2 3 4 5 
Very good 
Don’t know 
Symptom relief        
 
 1 
No side 
effects 
2 3 4 5 
Many side 
effects  
Don’t know 
Number of side effects       
 
 1 
Very bad  
2 3 4 5 
Very good 
Don’t know 
Type of “high”       
 
 1 
Very low 
2 3 4 5 
Very high 
Don’t know 
Level of harm       
 
 1 
Very 
difficult  
2 3 4 5 
Very easy 
Don’t know 
Accessibility (i.e., how easy it is 
to get) 
      
 
 1 2 3 4 5 Don’t know 
96 
 
Very low  Very high 
Cost (i.e., affordability)        
 
 1 
No stigma  
2 3 4 5 
A lot of 
stigma 
Don’t know 
Stigma (i.e., what other people 
think) 
      
 
 
 
 Probe: What does type of high mean to you?  
 Probe: Can you tell me in your own words what the level of harm question was asking you?  
 Probe: Why did you choose that response for accessible? Can you take me through your thinking 
process?   
 Probe: What does the term stigma mean to you? 
 Probe: How was it for you to go through that list?  Did that cause any difficulties? 
 
 
Forms of Marijuana  
 
Marijuana comes in many forms.  
Which form(s) of marijuana have you EVER used or tried? (select all that apply) 
1. Dried herb 
2. Hash (i.e., marijuana resin) 
3. Butter (i.e., to cook with) 
4. Oil 
5. Alcohol extract (i.e., tincture)  
6. Butane extract (i.e., shatter, wax)  
7. Carbon dioxide (CO2) extract 
8. Raw juice 
9. Synthetic marijuana (e.g., Marinol®/dronabinol, Cesamet®/nabilone, Sativex/nabiximol)  
10. Other (please specify) 
11. Don’t know 
12. Refuse to answer 
 
 Probe: Do the options in the list make sense to you?  
 
Programmer note: only ask if Form_cu=1-10 
Why do you currently use that form(s) of marijuana? (select all that apply) 
1. Effects last longer 
2. Effects occur faster 
3. Uses less marijuana  
4. Easy to use  
5. Easy to find the correct dose 
6. Provides the best symptom relief 
7. Less side effects  
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8. Provides the best high 
9. Less harmful 
10. More accessible (i.e., easy to get)  
11. More affordable 
12. More potent  
13. Higher quality 
14. Other (please specify):  
15. Don’t know 
Refuse to answer 
 
 Probe: Did you have any difficulties understanding any of these options? Do any of the options 
seem to not make sense or fit with the question?  
 
Do you usually use a specific strain(s) of marijuana? (select only one) 
1. Yes 
2. No 
3. Don’t know 
4. Not applicable  
Refuse to answer 
 
 Probe: What does strain mean to you?  
 
Do you know the tetrahydrocannabinol (THC), cannabidiol (CBD), or cannabinol (CBN) levels of the 
strain you use?  
1. Yes 
2. No 
3. Refuse to answer 
 
 Probe: Tell me what you were thinking when I asked about THC, CBD, and CBN.  
 
What are the tetrahydrocannabinol (THC), cannabidiol (CBD), or cannabinol (CBN) levels of the strain 
you use? 
Please specify in the boxes below:  
_____ THC 
_____CBD 
_____CBN 
 
 Probe: Was it easy or difficult to decide what answer to give? Were you able to give the answer you 
wanted to?  
 
 
Sources 
 
Which of the following ways have you EVER obtained marijuana for health reasons?  (select all that 
apply) 
1. From a Health Canada licensed producer 
2. Grow it yourself  
3. From a dispensary or club 
4. From another source through a designated-person production licence 
5. From a source without a license (e.g., friends, family, dealer) 
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6. Other (please specify): 
7. Don’t know 
8. Refuse to answer 
 
 Probe: How was it for you to go through that list?  Did that cause any difficulties? 
 
 
Stigma  
 
Please select the option you agree with:  
1. Society STRONGLY DISAPPROVES of medical marijuana 
2. Society DISAPPROVES of medical marijuana 
3. Neither DISAPPROVES or APPROVES of medical marijuana 
4. Society APPROVES of medical marijuana 
5. Society STRONGLY APPROVES of medical marijuana  
6. Don’t know 
7. Refuse to answer 
 
Please select the option you agree with:  
1. Society STRONGLY DISAPPROVES of recreational marijuana 
use 
2. Society DISAPPROVES of recreational marijuana use 
3. Neither DISAPPROVES nor APPROVES of recreational 
marijuana use 
4. Society APPROVES of recreational marijuana use 
5. Society STRONGLY APPROVES of recreational marijuana use 
6. Don’t know 
7. Refuse to answer 
 
Please select the option you agree with:  
Medical marijuana is…  
1. Not at all harmful to my health  
2. A little harmful to my health  
3. Somewhat harmful to my health 
4. Very harmful to my health 
5. Extremely harmful to my health 
6. Don’t know  
7. Refuse to answer 
 
Please select the option you agree with:  
Medical marijuana is… 
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1. Not at all addictive   
2. A little addictive  
3. Somewhat addictive 
4. Very addictive 
5. Extremely addictive 
6. Don’t know 
7. Refuse to answer 
 
Please select the option you agree with: 
Medical marijuana is… 
1. Definitely not a drug  
2. Not a drug 
3. Possibly a drug 
4. A drug 
5. Definitely a drug 
6. Don’t know 
7. Refuse to answer 
 
Medical marijuana is natural and is therefore… 
1. A LOT LESS harmful than other forms of medication 
2. A LITTLE LESS harmful than other forms of medication 
3. AS harmful AS other forms of medication 
4. A LITTLE MORE harmful than other forms of medication 
5. A LOT MORE harmful than other forms of medication 
6. Don’t know 
7. Refuse to answer 
 
Please select the option you agree with: 
SMOKING marijuana is…  
1. Not at all harmful to my health  
2. A little harmful to my health  
3. Somewhat harmful to my health 
4. Very harmful to my health 
5. Extremely harmful to my health 
6. Don’t know 
Refuse to answer   
 
 Probe: What does harm mean to you?  
 Probe: What does addiction mean to you?  
 Probe: Do all the possible answers seem okay, or did it seem like there’s one that’s supposed to be 
the right answer? 
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Vapourizer  
 
Please select the option you agree with: 
VAPOURIZING marijuana is…  
1. A LOT LESS acceptable than SMOKING marijuana 
2. A LITTLE LESS acceptable than SMOKING marijuana 
3. AS acceptable AS SMOKING marijuana  
4. A LITTLE MORE acceptable than SMOKING marijuana 
5. A LOT MORE acceptable than SMOKING marijuana  
6. Don’t know 
7. Refuse to answer  
 
Please select the option you agree with: 
VAPOURIZING marijuana is…  
1. Not at all harmful to my health  
2. A little harmful to my health  
3. Somewhat harmful to my health 
4. Very harmful to my health 
5. Extremely harmful to my health 
6. Don’t know 
7. Refuse to answer   
 
Please select the option you agree with: 
VAPOURIZING marijuana is…   
1. A LOT LESS harmful than SMOKING marijuana 
2. A LITTLE LESS harmful than SMOKING marijuana 
3. AS harmful AS SMOKING marijuana 
4. A LITTLE MORE harmful than SMOKING marijuana 
5. A LOT MORE harmful than SMOKING marijuana 
6. Don’t know 
7. Refuse to answer  
 
 Probe: Do all the possible answers seem okay, or did it seem like there’s one that’s supposed to be 
the right answer? 
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INTERVIEWER DEBRIEFING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interviewer Answer: 
1. (IATMO)  During the interview, was the atmosphere at the interview site: 
1. Extremely chaotic and noisy; disruptive to interview   
2. Some noise and interruptions, but interview went reasonably well  
3. Very quiet and calm; ideal for interview  
 
2. (IWHERE)  Where did the interview take place?  
___________________________________ 
 
3. (IHEAR) Were any other people in the same room or near enough to overhear 
the interview? 
1. Yes,   
3a.  (IWHO) Who were the people?  
__________________________________________ 
2. No 
 
4. (IIMPAIR)  Did the respondent have any of the following impairments making it 
difficult to respond? 
0. The respondent had no difficulty responding  
1. Mentally handicapped 
2. Hard of hearing/hearing impaired 
3. Poor eyesight/vision impaired 
4. Speech impediment 
5. Poor language abilities  
6. Under the influence of alcohol or drugs 
7. Some other impairment:  ____________________________________ 
 
5. (IVOCAB)  How would you describe the respondent’s vocabulary (the variety of 
words the respondent used to describe his/her thoughts)? 
1. Below average 
2. Average 
3. Above average 
 
6. (IACT)  In general, how did the respondent act toward you during the interview? 
1. Not at all attentive 
2. Somewhat attentive 
3. Very attentive 
 
7. (IQUESTION)  How much difficulty do you think the respondent had in 
understanding most of the questions? 
1. A lot of difficulty  
2. Some difficulty  
3. No difficulty  
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APPENDIX B 
 
Licensed producers 
1. Aphria 
2. Bedrocan Canada Inc.  
3. Broken Coast Cannabis Ltd.  
4. CanniMed Ltd.   
5. MariCann Inc.  
6. MedReleaf Corp.   
7. RedeCan Pharm  
8. The Peace Naturals Project Inc  
9. Whistler Medical Marijuana Corp. 
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APPENDIX C 
Survey 
 
SCREENER 
Welcome and thank you for your interest in this medical marijuana study. 
 
 
Before you begin, please answer a few short questions to ensure that you are eligible to 
participate. 
In this survey, when we use the term marijuana, we mean marijuana in any form including hashish, 
hash oil, synthetics, or other marijuana derivatives (e.g., edibles, extracts). 
 
Also, when we use the phrase ‘marijuana for health reasons’, we mean the use of marijuana for relief 
of health symptoms, also known as “medical marijuana”. 
Age 
Age 
Please enter your age:   [1-99 limit] 
 
 
Note: Only eligible if 18 years old or older 
Past 30 day use 
Past_30_day_use 
In the PAST 30 DAYS, have you used marijuana? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
 
Note: only eligible if answer is yes [1] 
Past 30 day Med Use 
Med_30_day_use 
In the PAST 30 DAYS, have you used marijuana (select only one) 
1.   For health reasons only (i.e., for relief of health symptoms), 
2.   For recreational purposes only (i.e., to get high, to be social), or 
3.   For both health and recreational purposes? 
4.   Don’t know 
5.   Refuse to answer 
 
Note: only eligible if answer is medical [1 or 3] 
License current 
License_cu 
Are you CURRENTLY approved to possess marijuana for health reasons in 
Canada? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
 
Note: only eligible if answer is yes [1] 
IF Ineligible: Unfortunately, you are not eligible for this survey. Thank you for your time. [Show this 
message after all questions then TERMINATE and block IP address if possible]. 
 
IF eligible: [continue] 
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Thank you. 
INTRODUCTION & CONSENT 
 
Please read the following information carefully. Once you have read the study details and agree to them, 
you can begin the survey. 
 
- You are being asked to participate in a research study about your opinions on medical marijuana. The 
goal of the survey is to increase our understanding of Canada’s policies on medical marijuana. The 
survey is being conducted by Professor David Hammond in the School of Public Health at the 
University of Waterloo, Canada. 
 
- You will be asked questions about marijuana use, beliefs about marijuana, ways of using 
marijuana, and some background information. 
 
- All of the information you provide in this study will be kept strictly confidential. Your identity and 
participation will not be disclosed to any outside group, including licensed medical marijuana 
providers, law enforcement, or government agencies unless required by law. 
 
- We will use your email address to send you $10 in appreciation of your time. Your email address will 
be stored in a different location than your survey answers and will be permanently deleted from all 
files immediately upon conclusion of the study. 
 
- The survey data will be retained for a minimum of 2 years and will be safely disposed of according 
to University of Waterloo policy; however, only the researchers directly associated with the study 
will have access to survey data. 
 
- Computer IP addresses will not be collected for security purposes. 
 
- The survey takes approximately 30 minutes to complete. 
 
- You must be 18 years of age or older to participate in this study. 
 
- Participation is voluntary and you may decline to answer particular questions if you wish. 
 
- You may only complete the survey once. 
 
- In appreciation of your time, you will receive $10, payable from your choice of an Interac e- 
transfer or an e-gift card from either Starbucks, Indigo/Chapters, Amazon.ca, iTunes, or Cineplex. 
The amount received is taxable. It is your responsibility to report this amount for income tax 
purposes. 
 
- The information provided in the surveys will be used in a thesis study as well as in other 
research papers by Dr. Hammond. 
- This survey uses surveygizmo, which is a United States of America company. Consequently, USA 
authorities under provisions of the PATRIOT Act may access this survey data. If you prefer not to submit 
your data through surveygizmo, please do not participate in the study. 
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- You are free to choose whether or not to participate in this study, and you can choose to stop being 
a part of it at any time without penalty. If you choose to withdraw from the survey, you must click 
through the entire survey until the final screen in order to receive payment. 
 
- This study has been reviewed by and has received ethics clearance through a University of Waterloo 
Research Ethics Committee. If you have any comments or concerns resulting from your involvement 
in this study, please contact the Chief Ethics Officer, Office of Research Ethics at 519-888-4567 ext. 
36005 or maureen.nummelin@uwaterloo.ca. 
 
- If you have any questions about the study you can contact Dr. David Hammond of the University of 
Waterloo at 519-888-4567 ext. 36462 or  dhammond@uwaterloo.ca. 
 
Based on the information you received, do you agree to take part in this research study being conducted by Dr. 
David Hammond of the University of Waterloo? 
1.   Yes 
2.   No 
 
IF YES: [continue] 
IF NO: Thank you for your time. [TERMINATE] Thank 
you. 
 
We are interested in your experiences and attitudes regarding marijuana. 
 
We understand that we are asking for sensitive information, so please keep in mind that your answers are 
completely confidential, and you will not be able to be identified. Please answer honestly and to the best of 
your ability – this is essential if the survey results are to be accurate. 
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PATTERNS OF USE 
 
 
FREQUENCY  
Past 3 month use 
Freq_3mnth 
In the PAST 3 MONTHS, on average, how often did you use marijuana (for any 
reason)? (select only one) 
1.   Every day 
2.   Almost every day 
3.   At least once a week 
4.   At least once a month 
5.   Less than once a month 
6.   Don't know 
7.   Refuse to answer 
Past 30 day use 
Freq_30day 
In the PAST 30 DAYS, on average, on how many of these days did you use 
marijuana (for any reason)? 
(if you refuse to answer this question, please enter 00) 
 
  [00-30 limit] 
Number of times 
per day 
Times_day 
In the PAST 30 DAYS, on average, on the days that you used marijuana (for any 
reason), how many times per day did you use it? 
1.   Once 
2.   Twice 
3.   3 times 
4.   4-5 times 
5.   More than 5 times 
6.   Don’t know 
7.   Refuse to answer 
AMOUNT 
Amount 
Amount_unit 
The next questions ask about the amount of marijuana you use (for any reason). 
 
Is it easier for you to say how much marijuana you use… 
1.   Per day, 
2.   Per week, or 
3.   Per month? 
4.   Don’t know 
5.   Refuse to answer 
Amount 
Amount_G 
Programmer note: if amount_unit=1 use “day”, if amount_unit=2,4,5 use “week”, 
if amount_unit=3 use “month” 
On average, how many GRAMS of marijuana do you use each 
[DAY/WEEK/MONTH]? 
(If you don’t know or refuse to answer, please enter 00) 
 
If less than 1 gram, please enter to one decimal place (e.g., 0.5) 
grams per [day, week, month]  [00-200] 
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COST  
The next questions ask about the cost of marijuana.  
Cost Frequency 
Cost_freq 
How often do you purchase marijuana? 
1.   Less than once every 3 months 
2.   Once every 2-3 months 
3.   Once a month 
4.   Once every 2-3 weeks 
5.   Once a week 
6.   More than once a week 
7.   Don’t know 
8.   Refuse to answer 
Cost Estimate 
Cost_est_week/mn 
th 
Programmer note: if Cost_freq=4,5,6,7,8 use “week”, Cost_freq=1,2,3 use 
“month”. 
Please estimate how much money you spend on marijuana each [WEEK/MONTH]. 
(If you don’t know or refuse to answer, enter 00) 
 
$   per [week/month] [00-1000] 
Cost coverage 
Cost_cov 
What percentage of the cost to purchase marijuana is covered through any type of 
insurance or plan? 
  _% [0-100] 
Cost coverage 
Cost_cov_who 
Programmer note: if Cost_cov is more than 0 
Which of the following covers the cost to purchase marijuana for you? 
 
1.   Veterans Affairs 
2.   Private insurer 
3.   Public/ government drug plan 
4.   Other, please specify 
5.   Don’t know 
6.   Refuse to answer 
MARIJUANA BEHAVIOURS 
The following questions ask about further details regarding marijuana use. 
Age of initiation 
Start_age 
How old were you when you first tried marijuana (for any reason)? 
(If you don’t know or refuse to answer, please enter 00) 
 
  [1-99] 
Age of Initiation 
Med 
Start_age_med 
How old were you when you first started using marijuana for health reasons? 
(If you don’t know or refuse to answer, please enter 00) 
 
  [1-99] 
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Waking 
Waking_5 
Waking_6_30 
Waking_31_60 
Waking_60_4 
Waking_more_4 
DK 
Refuse 
How soon after waking do you usually use marijuana (for any reason)? (select only 
one) 
1.   Within the first 5 minutes 
2.   6-30 minutes 
3.   31 – 60 minutes 
4.   60 minutes – 4 hours 
5.   More than 4 hours 
6.   Don’t know 
7.   Refuse to answer 
Length of time 
for medical use 
How long have you been using marijuana for health reasons? (select only one) 
1.   Less than 1 year 
Length 2.   1-2 years 
3.   3-5 years 
4.   6-10 years 
5.   More than 10 years 
6.   Don’t know 
7.   Refuse to answer 
Length of med 
use 
Future_length 
How long do you expect to continue using marijuana for health reasons? (select 
only one) 
1.   Less than 3 months 
2.   3 -6 months 
3.   6 months - 1 year 
4.   More than 1 year 
5.   Don’t know 
6.   Refuse to answer 
Medical Reasons Why did you decide to try marijuana for health reasons? (select all that apply) 
1.   Nothing else relieved my symptoms 
2.   Read about it 
3.   Suggested by a friend 
4.   Suggested by a family member 
5.   Suggested by a doctor 
6.   Suggested by another health practitioner 
7.   Prior use 
8.   Best treatment option available 
9.   Other (please specify): 
10. Don’t know 
11. Refuse to answer 
Recreational Use 
Rec_use 
Programmer note: only if Med_30_day_use=3 
Approximately, how much of your marijuana use is recreational (i.e., to get high, 
to be social)? 
1.   0% - I only use marijuana for health reasons 
2.   25% 
3.   50% 
4.   75% 
5.   100% - I only use marijuana for recreation reasons 
6.   Don’t know 
7.   Refuse to answer 
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MODE OF DELIVERY 
The next questions ask about different ways you may have used marijuana (for any reason). 
Ever mode 
(Mode_ever) 
Have you EVER tried or used marijuana in the following ways? (select all that 
apply) 
1.   Smoking a joint 
2.   Smoking a blunt 
3.   Smoking a pipe 
4.   Smoking a bong or waterpipe 
5.   Using a vapourizer 
6.   Eating in foods or baked goods (e.g., cookies, candy) 
7.   Drinking (e.g., tea) 
8.   Taking a pill (e.g., Marinol®/dronabinol or Cesamet®/nabilone) 
9.   Using a spray (e.g., Sativex/nabiximol) 
10. Other: [please specify] 
11. Don’t know 
12. Refuse to answer 
Current mode 
Mode_cu 
Programmer note: only bring up options selected in Mode_ever and only ask if 
Mode_ever=1-10. 
Have you used marijuana in the following ways in the PAST 30 DAYS? (select all 
that apply) 
1.   Don’t know 
2.   Refuse to answer 
3.   Smoking a joint 
4.   Smoking a blunt 
5.   Smoking a pipe 
6.   Smoking a bong or waterpipe 
7.   Using a vapourizer 
8.   Eating in foods or baked goods (e.g., cookies, candy) 
9.   Drinking (e.g., tea) 
10. Taking a pill (e.g., Marinol®dronabinol or Cesamet® nabilone) 
11. Using a spray (e.g., Sativex/nabiximol) 
12. Other: [insert] 
Multiple Modes 
Mode_multiple 
Programmer note: only bring up options selected in Mode_cu and only answer if 
Mode_cu= 1-10. 
 
We would like to know how much marijuana you use each way in the past 30 
days. 
Please enter the percentage of use for each in the boxes below (e.g. 50% smoking a 
joint, 50% eating in foods or baked goods). If you only selected one way of using 
marijuana, please enter 100%. 
 
                    (numerical: 0-100 and show %) 
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Preferred Mode 
Mode_prefer 
Programmer note: only ask if answered Mode_ever= 1-10. 
 
Which of the following is your most preferred way of using marijuana? (select only 
one) 
1.   Smoking a joint 
2.   Smoking a blunt 
3.   Smoking a pipe 
4.   Smoking a bong or waterpipe 
5.   Using a vapourizer 
6.   Eating in foods or baked goods (e.g., cookies, candy) 
7.   Drinking (e.g., tea) 
8.   Taking a pill (e.g., Marinol®dronabinol or Cesamet® nabilone) 
9.   Using a spray (e.g., Sativex/nabiximol) 
10. Other: [insert] 
11. Don’t know 
12. Refuse to answer 
Perception of 
Modes 
(Mode_perc) 
Smoking_, Vape_, 
Eat_ 
The next questions ask about three ways of using marijuana in more detail: 
 
1.   Smoking marijuana, 
2.   Using a vapourizer, and 
3.   Eating marijuana in foods. 
  
Compared to other ways of using marijuana, please rate [SMOKING/ USING A 
VAPOURIZER/ EATING IN FOODS] on the following factors: 
  1 
Very short 
2 3 4 5 
Very long 
Don’t 
know 
Refuse  
 
Duration of effect (i.e., how long it lasts) □ □ □ □ □ □ □ 
 
 1 
Very slow 
2 3 4 5 
Very quick 
Don’t 
know 
Refuse 
 
Time to onset of effect (i.e., how quickly 
the effects occur) 
       
 
 1 
Very low 
2 3 4 5 
Very high 
Don’t 
know 
Refuse 
 
The amount of marijuana needed for 
effect 
       
 
 1 
Very 
difficult 
2 3 4 5 
Very easy 
Don’t 
know 
Refuse 
 
Ease of use        
 
 1 
Very 
difficult 
2 3 4 5 
Very easy 
Don’t 
know 
Refuse 
 
Ability to find correct dose        
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 1 
Very bad 
2 3 4 5 
Very good 
Don’t 
know 
Refuse 
 
Symptom relief        
 
 1 
No side 
effects 
2 3 4 5 
Many side 
effects 
Don’t 
know 
Refuse 
 
Number of side effects        
 
 1 
Very bad 
2 3 4 5 
Very good 
Don’t 
know 
Refuse 
 
Type of “high”        
 
 1 
Very low 
2 3 4 5 
Very high 
Don’t 
know 
Refuse 
 
Level of harm        
 
 1 
Very 
difficult 
2 3 4 5 
Very easy 
Don’t 
know 
Refuse 
 
Accessibility (i.e., how easy it is to get)        
 
 1 
Very low 
cost 
2 3 4 5 
Very high 
cost 
Don’t 
know 
Refuse 
 
  Cost (i.e., affordability)         
 
 1 
No stigma 
2 3 4 5 
A lot of 
stigma 
Don’t 
know 
Refuse 
 
Stigma (i.e., what other people think)        
 
Programmer note: randomize order that the 3 ways are asked in and make sure 
method is very large. 
Important 
factors 
(Mode_factors) 
HOW IMPORTANT ARE EACH OF THE FACTORS TO YOU in your choice of how to 
use marijuana? 
  1 
Not at all 
important 
2 3 4 5 
Extremely 
important 
Don’t 
know 
Refuse  
 
Duration of effect (i.e., how long it lasts)        
Time to onset of effect (i.e., how quickly 
the effects occur) 
       
The amount of marijuana needed for 
effect 
       
Ease of use        
Ability to find correct dose        
Symptom relief        
Number of side effects        
Type of “high “        
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Level of harm        
Accessibility (i.e., how easy it is to get)        
Cost (i.e., affordability)        
Stigma (i.e., what other people think)        
Dabbing 
Dab_aware 
Have you EVER heard of DABBING marijuana? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Dabbing Ever 
Dab_ever 
Programmer note: only answer if Dab_aware=1 
Have you EVER tried DABBING marijuana? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
FORM 
Ever 
(Form_ever) 
Marijuana comes in many forms. 
Which form(s) of marijuana have you EVER used or tried? (select all that apply) 
1.   Dried herb 
2.   Marijuana resin (i.e., hash, kief, trichomes) 
3.   Butter (i.e., to cook with) 
4.   Oil 
5.   Alcohol extract (i.e., tincture) 
6.   Butane extract (i.e., shatter, wax, dabs) 
7.   Carbon dioxide (CO2) extract 
8.   Raw juice 
9.   Prescription marijuana (e.g., Marinol®/dronabinol, Cesamet®/nabilone, 
Sativex/nabiximol) 
10. Other (please specify) 
11. Don’t know 
12. Refuse to answer 
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Current 
Form_cu 
Programmer note: only bring up options selected in Form_ever and if answered 
Form_ever=1-10. 
In the PAST 30 DAYS, what was the MAIN form(s) of marijuana that you used? 
(select only one) 
1.   Don’t know 
2.   Refuse to answer 
3.   Dried herb 
4.   Marijuana resin (i.e., hash, kief, trichomes) 
5.   Butter (i.e., to cook with) 
6.   Oil 
7.   Alcohol extract (i.e., tincture) 
8.   Butane extract (i.e., shatter, wax, dabs) 
9.   Carbon dioxide (CO2) extract 
10. Raw juice 
11. Prescription marijuana (e.g., Marinol®/ dronabinol, Cesamet® / nabilone, 
Sativex/nabiximols) 
12. Other (please specify) 
Current other 
Form_cu_other 
Programmer note: only bring up options not selected in Form_cu and only if 
Form_ever=1-10. 
Have you used any other form(s) of marijuana in the PAST 30 DAYS? 
(select all that apply) 
1. No 
2. Dried herb 
3. Marijuana resin (i.e., hash, kief, trichomes) 
4. Butter (i.e., to cook with) 
5. Oil 
6. Alcohol extract (i.e., tincture) 
7. Butane extract (i.e., shatter, wax, dabs) 
8. Carbon dioxide (CO2) extract 
9. Raw juice 
10. Prescription marijuana (e.g., Marinol®/ dronabinol, Cesamet® / 
nabilone, Sativex/nabiximols) 
11. Other (please specify) 
12. Don’t know 
13. Refuse to answer 
Reason for form 
(Form_reason) 
Programmer note: only ask if Form_cu=1-10 
Why do you mainly use [fill from Form_current] form of marijuana? (select all that 
apply) 
1.   Effects last longer 
2.   Effects occur faster 
3.   Uses less marijuana 
4.   Easy to use 
5.   Easy to find the correct dose 
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 6.   Provides the best symptom relief 
7.   Less side effects 
8.   Provides the best high 
9.   Less harmful 
10. More accessible (i.e., easy to get) 
11. More affordable 
12. More potent 
13. Higher quality 
14. Recommended to me 
15. Other (please specify): 
16. Don’t know 
17. Refuse to answer 
Extract 
availability 
Extract_avail 
Programmer note: only ask if Form_cu=1, 2, 3, 8, 9, 10, 11, 12 
Marijuana extracts have high concentrations of cannabinoids due to an extraction 
process using alcohol, carbon dioxide (CO2), or butane, and may come in the form 
of oil, butter, or wax. 
 
Would you try marijuana extracts (e.g., alcohol, butane, carbon dioxide) if they 
were available to you? (select only one) 
1.   Definitely not 
2.   Probably not 
3.   Maybe 
4.   Probably yes 
5.   Definitely yes 
6.   Don’t know 
7.   Refuse to answer 
Strains 
Strain_YN 
Do you usually use a specific strain(s) of marijuana? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Not applicable 
5.   Refuse to answer 
Strains 
Strain_name 
Programmer note: only ask if Strain_YN=1 
Please specify the strain(s): [open-ended text] 
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Strains 
(Strain_reason) 
Programmer note: only if Strain_YN=1 
Why do you use that specific strain(s) of marijuana? (select all that apply) 
1.   Effects last longer 
2.   Effects occur faster 
3.   Uses less marijuana 
4.   Provides the best symptom relief 
5.   Less side effects 
6.   Provides the best high 
7.   Less harmful 
8.   More accessible (i.e., easy to get) 
9.   More affordable 
10. More potent 
11. Higher quality 
12. Recommended to me 
13. Tetrahydrocannabinol (THC) levels 
14. Cannabidiol (CBD) levels 
15. Cannabinol (CBN) levels 
16. Other (please specify): 
17. Don’t know 
18. Refuse to answer 
Strains 
Strain_levels_YN 
Programmer note: only if Strain_YN=1 
Do you know the tetrahydrocannabinol (THC) and cannabidiol (CBD) levels of the 
main strain you use? 
1.   Yes 
2.   No 
3.   Refuse to answer 
Strains 
Strain_levels 
Programmer note: if Strain_levels_YN=1 (yes) 
What are the tetrahydrocannabinol (THC) and cannabidiol (CBD) levels of the main 
strain you use? Please specify in the boxes below: 
  THC 
  _CBD 
Strains 
Strain_levels_look 
Programmer note: if Strain_levels_YN=1 (yes) 
 
When answering the last question, did you look at your bottle of medical marijuana 
for this information? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
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Strains 
Strain_relief 
Programmer note: only if Strain_YN=1 
How effective is the strain(s) you usually use in alleviating your symptoms… (select 
only one) 
1.   Very ineffective 
2.   Ineffective 
3.   In the middle 
4.   Effective 
5.   Very effective 
6.   Don’t know 
7.   Refuse to answer 
Strains 
Strain_avail 
Programmer note: only if Strain_YN=1 
Would you try different strains of marijuana if they were available? (select only 
one) 
1.   Definitely not 
2.   Probably not 
3.   Maybe 
4.   Probably yes 
5.   Definitely yes 
6.   Don’t know 
7.   Refuse to answer 
 
REASONS FOR USE 
 
 
 
The next questions ask about your reasons for using marijuana. Remember that your answers are strictly 
confidential. Please be as honest as possible. 
Prescription 
Prescrip_cu 
Do you CURRENTLY have a medical document to use marijuana from a 
physician? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Prescription Length 
of Time 
Prescrip_time_cu 
Programmer note: only if Prescrip_cu=1 
How long have you had a medical document to use marijuana? (select only 
one) 
1.   Less than 1 year 
2.   1-2 years 
3.   3-5 years 
4.   6-10 years 
5.   More than 10 years 
6.   Don’t know 
7.   Refuse to answer 
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Type of license ever 
(License_type_ever) 
Have you EVER been approved to possess marijuana for medical purposes 
under the … (select all that apply) 
1.   Marihuana Medical Access Regulations (MMAR), issued from June 14, 
2001 until March 31, 2014 
2.   Marihuana for Medical Purposes Regulations (MMPR), issued starting 
April 1, 2014 
3.   Don’t know 
4.   Refuse to answer 
Type of license 
current 
License_type_current 
Programmer note: only if License_type_ever=1,2 
Are you CURRENTLY approved to possess marijuana for medical purposes 
under the … (select only one) 
1.   Marihuana Medical Access Regulations (MMAR), issued from June 14, 
2001 until March 31, 2014 
2.   Marihuana for Medical Purposes Regulations (MMPR), issued starting 
April 1, 2014 
3.   Don’t know 
4.   Refuse to answer 
Current License 
Length of Time 
License_time_cu 
Programmer note: only if License_type_current=1,2 
In total, how long have you been approved to use medical marijuana in 
Canada? 
1.   Less than 1 year 
2.   1-2 years 
3.   3-5 years 
4.   6-10 years 
5.   More than 10 years 
6.   Don’t know 
7.   Refuse to answer 
Medical conditions 
Med_conditions 
Which of the following condition(s) do you use marijuana for? (select all that 
apply) 
1.   Chronic pain (e.g., arthritis, back pain, migraine) 
2.   Nausea or vomiting 
3.   Lack of appetite or weight loss 
4.   Depression 
5.   Multiple sclerosis or spinal cord injury 
6.   Epilepsy 
7.   Anxiety or nerves 
8.   Glaucoma 
9.   Insomnia 
10. Other (please specify) 
11. Don't know 
12. Refuse to answer 
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Medical Conditions 
Med_main_condition 
Programmer note: only if Med_conditions=1-10 and only bring up options 
selected in Med_conditions. 
What is the MAIN condition that you use marijuana for? (select only one) 
1.   Chronic pain (e.g., arthritis, back pain, migraine) 
2.   Nausea or vomiting 
3.   Lack of appetite or weight loss 
4.   Depression 
5.   Multiple sclerosis or spinal cord injury 
6.   Epilepsy 
7.   Anxiety or nerves 
8.   Glaucoma 
9.   Insomnia 
10. Other (please specify) 
11. Don't know 
12. Refuse to answer 
Life threatening 
illness 
Palliative 
Do you use medical marijuana to treat a life threatening medical condition with 
a prognosis of less than one year? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Smoking Illness 
Smoke_Illness 
Do you have any respiratory illnesses (e.g., asthma, COPD, lung cancer)? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
 
SIDE EFFECTS 
 
Cough 
Cough 
Do you usually have a cough? 
1.   Yes 
2.   Sometimes 
3.   No 
4.   Don’t know 
5.   Refuse to answer 
Chest wheezy 
Chest_wheezy 
Does your chest sound wheezy or whistling other than from colds? 
1.   Yes 
2.   Sometimes 
3.   No 
4.   Don’t know 
5.   Refuse to answer 
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Breath 
Breath 
Are you troubled by shortness of breath when hurrying on the level ground 
or walking up a slight hill? 
1.   Yes 
2.   Sometimes 
3.   No 
4.   Don’t know 
5.   Refuse to answer 
Walk slow 
Walk_slow 
Do you have to walk slower than most people your own age on the level 
ground because of breathlessness? 
1.   Yes 
2.   Sometimes 
3.   No 
4.   Don’t know 
5.   Refuse to answer 
Phlegm 
Phlegm 
Do you cough up phlegm in the morning? 
1.   Yes 
2.   Sometimes 
3.   No 
4.   Don’t know 
5.   Refuse to answer 
Chest tightness 
Chest_tight 
Do you wake up at night with tightness in your chest? 
1.   Yes 
2.   Sometimes 
3.   No 
4.   Don’t know 
5.   Refuse to answer 
Side Effects 
(Side_effects) It’s a 
check all 
Have you EVER experienced any of the following from using marijuana for 
health reasons? (select all that apply) 
1.   Feeling quiet or disconnected 
2.   Drowsiness or laziness 
3.   Feeling high 
4.   Loss of appetite 
5.   Increased appetite 
6.   Loss of balance 
7.   Weakness 
8.   Confused or forgetful thinking 
9.   Slurred speech 
10. Dry mouth 
11. Headache 
12. Blurred vision 
13. Shaking 
14. Sweating 
15. Dehydration 
16. Nausea 
17. Increased heart rate or palpitations 
18. Anxiety 
19. Paranoia or hallucinations 
20. Other (please specify): 
21. None 
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20. Other (please specify): 
21. None 
22. Don’t know 
23. Refuse to answer 
 
 
 
 
ACCESSIBILITY 
The next questions ask about the accessibility of marijuana. As a reminder, all of the information you 
provide will be kept strictly confidential. Please be as honest as possible. 
Ever 
(Source_ever) check 
all 
Which of the following ways have you EVER obtained marijuana for health 
reasons? (select all that apply) 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From a dispensary or club 
4.   From another source through a designated-person production 
licence 
5.   From a source without a license (e.g., friends, family, dealer) 
6.   Other (please specify): 
7.   Don’t know 
8.   Refuse to answer 
Main 
Source_main 
Which of the following is the MAIN way you obtain marijuana for health 
reasons? (select only one) 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From a dispensary or club 
4.   From another source through a designated-person production 
licence 
5.   From a source without a license (e.g., friends, family, dealer) 
6.   Other (please specify): 
7.   Don’t know 
8.   Refuse to answer 
Preferred 
Source_prefer 
Which of the following is your most PREFERRED way of obtaining marijuana 
for health reasons? (select only one) 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From a dispensary or club 
4.   From another source through a designated-person production 
licence 
5.   From a source without a license (e.g., friends, family, dealer) 
6.   Other (please specify): 
7.   Don’t know 
8.   Refuse to answer 
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Access Comparison 
Source_comp 
 
Source_comp_cost1 
 
 
 
 
 
 
 
 
Source_comp_cost2 
 
 
 
 
 
 
 
 
 
Source_comp_time1 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_time2 
 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_access1 
We would like your opinion on three different ways of obtaining marijuana: 
from a Health Canada licensed producer, growing it yourself, and from 
another unlicensed source (e.g., friends, family, dealer). 
 
From which of the following sources is medical marijuana MOST 
EXPENSIVE? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
From which of the following sources is medical marijuana LEAST 
EXPENSIVE? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
 
 
From which of the following sources does it take the MOST AMOUNT OF 
TIME TO RECEIVE medical marijuana? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
 
 
From which of the following sources does it take the LEAST AMOUNT OF 
TIME TO RECEIVE medical marijuana? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer 
4.   Don’t know 
5.   Refuse to answer 
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Source_comp_access
2 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_safe1 
 
 
 
 
 
 
 
 
 
Source_comp_safe2 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_qual1 
 
 
 
 
 
 
 
 
 
Source_comp_qual2 
From which of the following sources is obtaining medical marijuana MOST 
ACCESSIBLE (i.e., how easy it is to get)? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
From which of the following sources is obtaining medical marijuana LEAST 
ACCESIBLE (i.e., how easy it is to get)? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
 
 
Which of the following sources has the HIGHEST SAFETY STANDARDS for 
medical marijuana? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
Which of the following sources has the LOWEST SAFETY STANDARDS for 
medical marijuana? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer 
4.   Don’t know 
5.   Refuse to answer 
 
 
 
Which of the following sources has the HIGHEST QUALITY (i.e., look, feel, smell) 
of medical marijuana? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
Which of the following sources has the LOWEST QUALITY (i.e., look, feel, smell) 
of medical marijuana? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer 
4.   Don’t know 5.   Refuse to answer 
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Source_comp_potent1 
 
 
 
 
 
 
 
 
 
Source_comp_potent2 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_relief1 
 
 
 
 
 
 
 
 
 
Source_comp_relief2 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_stigma1 
 
 
 
 
 
 
 
 
 
 
 
Source_comp_stigma2 
From which of the following sources is medical marijuana the MOST 
POTENT? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
From which of the following sources is medical marijuana the LEAST 
POTENT? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
 
 
Which of the following sources provides medical marijuana with the BEST 
SYMPTOM RELIEF? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
Which of the following sources provides medical marijuana with the WORST 
SYMPTOM RELIEF? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
 
 
From which of the following sources is obtaining medical marijuana 
associated with the MOST STIGMA (i.e., negative thoughts from other 
people)? 
1.   From a Health Canada licensed producer 
2.   Grow it yourself 
3.   From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
From which of the following sources is obtaining medical marijuana 
associated with the LEAST STIGMA (i.e., negative thoughts from other 
people)? 
1.   From a Health Canada licensed producer 
2.     Grow it yourself
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3. From another unlicensed source (e.g., friends, family, dealer) 
4.   Don’t know 
5.   Refuse to answer 
 
Programmer note: use logic to only allow answers not selected in the first 
part to appear and skip next question if selected don’t know or refuse to 
answer. 
 
 
 
 
STIGMA 
 
SUPPORT 
The next questions ask about your experiences with marijuana for health reasons. Please remember 
there are no right or wrong answers - we are most interested in your thoughts. 
Doctor 
Doctor 
Do you currently have a physician (or general practitioner)? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Recommendation 
Recom_doc 
Did a physician or nurse practitioner ever recommend that you use 
medical marijuana? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Recommendation 
Recom_altern 
Did an alternative health practitioner (e.g., naturopath, chiropractor, 
homeopath) ever recommend that you use medical marijuana? (select 
only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Support 
Support_doc_1 
Programmer note: if Doctor=1 
What is your PHYSICIAN(S)’S general attitude towards your marijuana 
use for health reasons? (select only one) 
1.   Very Unsupportive 
2.   Unsupportive 
3.   Neutral 
4.   Supportive 
5.   Very supportive 
6.   Don’t know 
7.   Refuse to answer 
120 
 
Support 
Doctor_refuse 
Has a physician EVER refused to give you a medical document to use 
marijuana for health reasons? (select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Support 
(Doctor_refuse_reasons) 
Check all 
Programmer note: if Doctor_refuse=1 
What was the physician’s reason for refusing to give you a medical 
document to use marijuana for health reasons? 
1.   Advised that you were not yet sick enough to need marijuana 
2.   Feared repercussions from the medical association 
3.   Other (please specify): 
4.   Don’t know 
5.   Refuse to answer 
Support 
Doctor_fee 
Have you EVER had to pay any sort of fee for a medical document to use 
marijuana? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Support 
Support_family 
What is your FAMILY’S general attitude toward your marijuana use for 
health reasons? (select only one) 
1.   Very Unsupportive 
2.   Unsupportive 
3.   Neutral/ Mixed Support 
4.   Supportive 
5.   Very Supportive 
6.   They do not know I use marijuana 
7.   Other (please specify): 
8.   Don’t know 
9.   Refuse to answer 
Support 
Support_friends 
What are your FRIENDS’ general attitude towards your marijuana use for 
health reasons? (select only one) 
1.   Very Unsupportive 
2.   Unsupportive 
3.   Neutral/ Mixed Support 
4.   Supportive 
5.   Very Supportive 
6.   They do not know I use marijuana 
7.   Other (please specify): 
8.   Don’t know 
9.   Refuse to answer 
Hiding use from 
friends 
Hide_friends 
Do you hide your marijuana use for health reasons from… 
1.   None of your friends 
2.   Some of your friends 
3.   All of your friends 
4.   Refuse to answer 
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Hiding use from family 
Hide_family 
Do you hide your marijuana use for health reasons from… 
1.   None of your family 
2.   Some of your family 
3.   All of your family 
4.   Refuse to answer 
Hiding use at work 
Hide_work 
Do you hide your marijuana use from… 
1.   None of the people at work 
2.   Some of the people at work 
3.   All of the people at work 
4.   I don’t work 
5.   Refuse to answer 
Hiding use 
(Hide_reasons) Check all 
What are your reasons for hiding your marijuana use? (select all that 
apply) 
1.   Respect for the feelings of nonusers 
2.   Avoiding judgement 
3.   Setting an example for children 
4.   Fear of legal punishment 
5.   Privacy 
6.   I don’t hide my marijuana use 
7.   Other (please specify): 
8.   Don’ t know 
9.   Refuse to answer 
Concern for med use 
Med_use_concern 
Do you fear legal punishment due to your use of marijuana for health 
reasons? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
The next questions ask about your beliefs and opinions on marijuana. 
Society approval 
Society_med_approval 
Please select the option you agree with: 
1.   Society STRONGLY DISAPPROVES of medical marijuana 
2.   Society DISAPPROVES of medical marijuana 
3.   Neither DISAPPROVES or APPROVES of medical marijuana 
4.   Society APPROVES of medical marijuana 
5.   Society STRONGLY APPROVES of medical marijuana 
6.   Don’t know 
7.   Refuse to answer 
Society approval 
Society_rec_approval 
Please select the option you agree with: 
1.   Society STRONGLY DISAPPROVES of recreational marijuana use 
2.   Society DISAPPROVES of recreational marijuana use 
3.   Neither DISAPPROVES nor APPROVES of recreational marijuana 
use 
4.   Society APPROVES of recreational marijuana use 
5.   Society STRONGLY APPROVES of recreational marijuana use 
6.   Don’t know 
7.   Refuse to answer 
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Addictive 
Perc_addictive 
Please select the option you agree with: 
Medical marijuana is… 
1.   Not at all addictive 
2.   A little addictive 
3.   Somewhat addictive 
4.   Very addictive 
5.   Extremely addictive 
6.   Don’t know 
7.   Refuse to answer 
SMOKING HEALTH RISK PERCEPTION 
The next question asks about SMOKING marijuana, as a joint, blunt, in a pipe, bong, waterpipe, etc. 
Please indicate whether you agree with the following statement. 
Smoking Harm Please select the option you agree with:  
Smoke_harm SMOKING marijuana is… 
1.   Not at all harmful to my health 
2.   A little harmful to my health 
3.   Somewhat harmful to my health 
4.   Very harmful to my health 
5.   Extremely harmful to my health 
6.   Don’t know 
7.   Refuse to answer  
  
 
 
 
VAPOURIZERS 
 
The next questions ask about VAPOURIZING or VAPING marijuana. Vapourization is defined as 
inhaling the vapour produced by heating marijuana in devices such as an inflatable bag (e.g., 
Volcano), portable vapourizer (e.g., Launch box, Pax), e-cigarette, or vape pen. 
Awareness 
Vape_aware 
Had you EVER heard of VAPOURIZING or VAPING marijuana before this study? 
(select only one) 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
PATTERNS OF USE 
Frequency 
Vape_freq 
Programmer note: only if mode_ever=5 
In the PAST 30 DAYS, how often did you use a VAPOURIZER with marijuana 
(for any reason)? (Select only one) 
1.   Not at all 
2.   At least once in the last 30 days 
3.   At least once a week 
4.   Almost every day 
5.   Every day 
6.   Don’t know 
7.   Refuse to answer 
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Vape form Ever 
(Vape_form_ever) 
Check all 
Programmer note: only if mode_ever=5 
Which form(s) of marijuana have you EVER used in a VAPOURIZER? (select all 
that apply) 
1.   Dried herb 
2.   Marijuana resin (i.e., hash, kief, trichomes) 
3.   Oil 
4.   Alcohol extract (tincture) 
5.   Butane extract (i.e., shatter, wax, dabs) 
6.   Carbon dioxide (CO2) extract 
7.   Other (please specify): 
8.   Don’t know 
9.   Refuse to answer 
Vape Form 
Current 
(Vape_form_cu) 
Check all 
Programmer note: only if Vape_freq=2,3,4,5 and if 
Vape_form_ever=1,2,3,4,5,6,7. 
In the PAST 30 DAYS, which form(s) of marijuana did you use in a 
VAPOURIZER? (select all that apply) 
1.   Dried herb 
2.   Marijuana resin (i.e., hash, kief, trichomes) 
3.   Oil 
4.   Alcohol extract (tincture) 
5.   Butane extract (i.e., shatter, wax, dabs) 
6.   Carbon dioxide (CO2) extract 
7.   Other (please specify): 
8.   Don’t know 
9.   Refuse to answer 
Type Ever use 
(Type_ever) Check 
all 
Programmer note: only if mode_ever=5 
 
 
Which type(s) of VAPOURIZER(S) have you EVER tried? (Select all that apply) 
 
 
1.   Stationary vapourizer (e.g., Volcano, Extreme Q) 
2.   Portable vapourizer (e.g., Magic Flight Launch Box, Pax) 
3.   E-cigarette or vape pen 
4.   Made my own 
5.   Other (please specify): 
6.   Don’t know 
7.   Refuse to answer 
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Type Current use 
(Type_cu) Check all 
Programmer note: only if Vape_freq=2,3,4,5 and if Type_ever=1,2,3,4,5, pipe 
from Type_ever. 
 
 
In the PAST 30 DAYS, which type(s) of VAPOURIZER(S) did you use? 
 
 
1.   Stationary vapourizer (e.g., Volcano, Extreme Q) 
2.   Portable vapourizer (e.g., Magic Flight Launch Box, Pax) 
3.   E-cigarette or vape pen 
4.   Made my own 
5.   Other (please specify): 
6.   Don’t know 
7.   Refuse to answer 
REASONS 
Reasons for 
Current use 
(Vape_reasons_cu) 
Check all 
Programmer note: only if Vape_freq=2,3,4,5 
 
 
Why do you CURRENTLY use a VAPOURIZER? (select all that apply) 
 
 
1.   Effects last longer 
2.   Effects occur faster 
3.   Uses less marijuana 
4.   Easy to use 
5.   Easy to find the correct dose 
6.   Provides the best symptom relief 
7.   Less side effects 
8.   Provides the best high 
9.   It might be less harmful to me than smoking marijuana 
10. It might be less harmful to people around me than smoking marijuana 
11. More accessible (i.e., easy to get) 
12. More affordable 
13. Other people I know use a vapourizer too 
14. It’s fun to use 
15. It doesn’t smell as much as smoking marijuana 
16. Other (please specify): 
17. Don’t know 
18. Refuse to answer 
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Reasons for NOT 
using 
Vape_abst 
Programmer note: if vape_aware=1 and mode_ever=1-4, 6-12 
 
 
What is the MAIN reason why you DO NOT use a VAPOURIZER? (select only 
one) 
 
 
1.   Effects don’t last long 
2.   Effects occur too slowly 
3.   Uses more marijuana 
4.   Difficult to use 
5.   Difficult to find the correct dose 
6.   Doesn’t provide the best symptom relief 
7.   More side effects 
8.   Doesn’t provide the best high 
9.   It’s harmful 
10. Less accessible (i.e., difficult to get) 
11. Less affordable 
12. I’m concerned about what people might think 
13. I’m not interested 
14. Other (please specify): 
15. Don’t know 
16. Refuse to answer 
Vape 
Acceptability 
Vape_accept 
Programmer note: only if Vape_aware=1 
Please select the option you agree with: 
VAPOURIZING marijuana is… 
1.   A LOT LESS acceptable than SMOKING marijuana 
2.   A LITTLE LESS acceptable than SMOKING marijuana 
3.   AS acceptable AS SMOKING marijuana 
4.   A LITTLE MORE acceptable than SMOKING marijuana 
5.   A LOT MORE acceptable than SMOKING marijuana 
6.   Don’t know 
7.   Refuse to answer 
Vapourizer Harm 
Vape_harm_1 
Programmer note: only if Vape_aware=1 
VAPOURIZING marijuana is… 
1.   Not at all harmful to my health 
2.   A little harmful to my health 
3.   Somewhat harmful to my health 
4.   Very harmful to my health 
5.   Extremely harmful to my health 
6.   Don’t know 
7.   Refuse to answer 
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Vape Harm 
compared to 
smoke 
Vape_harm_2 
Programmer note: only if Vape_aware=1 
VAPOURIZING marijuana is… 
1.   A LOT LESS harmful than SMOKING marijuana 
2.   A LITTLE LESS harmful than SMOKING marijuana 
3.   AS harmful AS SMOKING marijuana 
4.   A LITTLE MORE harmful than SMOKING marijuana 
5.   A LOT MORE harmful than SMOKING marijuana 
6.   Don’t know 
7.   Refuse to answer 
WILLINGNESS TO TRY/USE A VAPOURIZER 
Future Vape 
Vape_future 
Programmer note: only if vape_aware=1 and mode_ever=1-4, 6-12 
In the future, do you think you might try VAPOURIZING marijuana? 
1.   Definitely not 
2.   Probably not 
3.   Maybe 
4.   Probably yes 
5.   Definitely yes 
6.   Don’t know 
7.   Refuse to answer 
 
 
 
 
TOBACCO USE 
 
The next questions are about TOBACCO and nicotine use. 
Tobacco 100 cigs 
Tob_100cigs 
Have you smoked at least 100 cigarettes in your life? 
1.   Yes 
2.   No 
3.   Don’t know 
4.   Refuse to answer 
Tobacco 
Frequency 
Tob_freq 
At the present time, do you smoke cigarettes not at all, occasionally, or daily? 
1.   Not at all 
2.   Occasionally 
3.   Daily 
4.   Don’t know 
5.   Refuse to answer 
Tobacco 
Tob_mj 
When you use marijuana, do you mix it with tobacco? 
1.   Never 
2.   Sometimes 
3.   Often 
4.   Always 
5.   Don’t know 
6.   Refuse to answer 
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E-cigarette ever 
use 
Ecig_ever 
Have you EVER used an e-cigarette or a vapourized nicotine product (e.g., 
electronic cigarette), even one or two times? 
 
1. Yes 
2. No 
3. Don’t know 
4. Refuse to answer 
E-cigarette current 
use 
Ecig_cu 
Programmer Note: Ask only if Ecig_ever =1 
 
 
In the PAST 30 DAYS, how often did you vapourize nicotine? 
 
1. Not at all 
2. Less than once a month 
3. At least once a month 
4. At least once a week 
5. Almost every day 
6. Every day 
7. Don't know 
8. Refuse to answer 
 
 
 
DEMOGRAPHICS 
 
The last few questions ask about your background. 
 
 
 
 
 
 
 
 
Trap 
Trap 
What month are you completing this survey in? 
1.   January 
2.   February 
3.   March 
4.   April 
5.   May 
6.   June 
7.   July 
8.   August 
9.   September 
10. October 
11. November 
12. December 
13. Don’t know 
14. Refuse to answer 
 
Gender 
Gender 
Are you… 
1. Male 
2. Female 
3. Refuse to answer 
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Province 
Province 
What province or territory do you live in? 
1.   Alberta 
2.   British Columbia 
3.   Manitoba 
4.   New Brunswick 
5.   Newfoundland & Labrador 
6.   Nova Scotia 
7.   Northwest Territories 
8.   Nunavut 
9.   Ontario 
10. Prince Edward Island 
11. Quebec 
12. Saskatchewan 
13. Yukon 
14. Refuse to answer 
Ethnicity/ 
Race 
(Race – check all) 
People in Canada come from many racial and cultural groups. Do you self- 
identify as… 
(Select all that apply) 
1. White 
2. South Asian (e.g., East Indian, Pakistani, Sri Lankan) 
3. Chinese 
4. Black 
5. Filipino 
6. Latin American 
7. Arab 
8. Southeast Asian (e.g., Vietnamese, Cambodian, Malaysian, Laotian) 
9. West Asian (e.g., Iranian, Afghan) 
10. Korean 
11. Japanese 
12. Aboriginal (e.g., First Nations, Métis, Inuk/Inuit) 
13. Other (please specify):   [open-ended text] 
14. Don’t know 
15. Refuse to answer 
Level of education 
 
 
Education 
What is the highest level of formal education that you have completed? 
1.  Grade school 
2.  Some high school 
3.  Completed high school 
4.  Technical/trade school or community college 
5.  Some university, no degree 
6.  Completed university degree 
7.  Masters, PhD or other post-graduate degree 
8.  Don’t know 
9.  Refuse to answer 
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Employment 
status 
Occup 
Which of the following best describes your main employment status over the 
PAST 12 MONTHS? 
1. Employed full-time 
2. Employed part-time 
3. Attending school full-time 
4. Attending school part-time 
5. Homemaker 
6. Retired 
7. Unemployed, able to work 
8. Unemployed, unable to work 
9. Other (please specify):   [open-ended text] 
10. Don’t know 
11. Refuse to answer 
Income 
Income 
What is your best estimate of your TOTAL PERSONAL INCOME before taxes and 
other deductions, from all sources, such as savings, pensions, rent and 
unemployment insurance as well as wages, received in the past 12 months? 
1.   Less than $20,000 
2.   $20,000 to $40,000 
3.   $40,001 to $60,000 
4.   $60,001 to $80,000 
5.   $80,001 to $100,000 
6.   More than $100,000 
7.   Don’t know 
8.   Refuse to answer 
Survey 
(Survey- check all) 
How did you find out about this survey? (select all that apply) 
1.   Health Canada-licensed marijuana producer 
2.   Medical marijuana club 
3.   Medical marijuana clinic 
4.   Marijuana dispensary 
5.   Friend 
6.   Family member 
7.   Online 
8.   Social media 
9.   Other (please specify): 
10. Don’t know 
11. Refuse to answer 
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Survey Producer 
(Survey_producer – 
check all) 
Which Health Canada licensed marijuana producer do you order your medical 
marijuana from? 
 
 
As a reminder, we will not inform any group, including licensed producers about 
your participation in this survey and your answers will be kept strictly 
confidential. 
(select all that apply) 
 
 
1.   Aphria 
2.   Bedrocan Canada Inc. 
3.   Broken Coast Cannabis Ltd. 
4.   Canna Farms Ltd. 
5.   CanniMed Ltd. 
6.   Delta 9 Bio-Tech Inc. 
7.   In The Zone Produce Ltd. 
8.   MariCann Inc. 
9.   MedReleaf Corp. 
10. Mettrum Ltd. 
11. OrganiGram Inc. 
12. The Peace Naturals Project Inc. 
13. Tilray 
14. Tweed Inc. 
15. Whistler Medical Marijuana Corp 
16. Don’t know 
17. Refuse to answer 
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E-TRANSFER QUESTIONNAIRE TEXT 
 
 
 
Gift card 
Gift_card 
You’re finished! Thanks again for your help. 
 
 
 
How would you like to receive your $10.00? Choose one of the options below and 
we’ll send you the electronic payment or gift card within 2 business days. 
 
1.   Interac e-transfer 
2.   Starbucks e-gift card 
3.   iTunes e-gift card 
4.   Cineplex e-gift card 
5.   Indigo/Chapters e-gift card 
6.   Amazon.ca e-gift card 
7.   I do not wish to receive any payment 
Etransfer Programmer note: If giftcard=1, ask: 
 
To receive the Interac e-transfer, you must have online banking at a participating 
Canadian financial institution. Please confirm that you bank at one of the following 
institutions: 
 
Bank of Canada 
BMO 
CIBC 
DC Bank 
ING 
Prospera Credit Union 
RBC Royal Bank 
Scotiabank 
TD Canada Trust 
 
1  Yes 
2 No: please select an e-gift card from the next screen 
 
[Programmer note: if select no (etransfer=2), please return to previous screen (giftcard) 
without option 1] 
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Gift_card_2 
 
How would you like to receive your $10.00? Choose one of the options below and 
we’ll send you the electronic payment or gift card within 2 business days. 
 
1.   Starbucks e-gift card 
2.   iTunes e-gift card 
3.   Cineplex e-gift card 
4.   Indigo/Chapters e-gift card 
5.   Amazon.ca e-gift card 
6.   I do not wish to receive any payment 
Password Programmer note: If etransfer=1, ask: 
 
You will need a password to accept the $10 payment. The password is “marijuana”. 
That’s all the questions we have for you today. 
 
Thank you for participating in our study – we appreciate your help. 
 
As a reminder, this study is confidential and has been reviewed by and received ethics clearance through a 
University of Waterloo Research Ethics Committee. If you have any comments or concerns resulting from 
your involvement please contact either the Chief Ethics Office, Office of Research Ethics, at 519-888-4567, 
ext. 36005 or maureen.nummelin@uwaterloo.ca, or Professor David Hammond at 519-888-4567, ext. 36462 
or dhammond@uwaterloo.ca. 
 
If you would like any further information about the study, including a copy of our findings when they become 
available, please contact Dr. David Hammond at 519-888-4567 ext. 36462 or dhammond@uwaterloo.ca. 
 
We really appreciate your participation and hope that this has been an interesting experience for you. 
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APPENDIX D 
Table 13: Current Mode of Delivery Logistic Regression Model Output (n=250) (C-statistic=0.83) 
Covariates OR 95% CI P-value 
    
Gender  1.49 0.64-3.45 0.36 
    
Age  1.03 1.00-1.06 0.08 
    
Ethnicity  2.09 0.60-7.33 0.25 
    
Education   0.01 
Low vs. Moderate 1.40 0.44-4.36 0.59 
Low vs. High  4.92 1.44-16.84 0.01 
High vs. Moderate  0.20 0.06-0.70 0.01 
    
Income   0.15 
Low vs. Middle 0.35 0.12-1.02 0.06 
Low vs. High 0.58 0.19-1.76 0.34 
High vs. Middle 1.73 0.57-5.28 0.34 
    
Region   0.46 
Atlantic vs. Quebec 1.01 0.04-24.61 0.99 
Atlantic vs. Prairies  1.19 0.14-10.46 0.88 
Atlantic vs. British Columbia 1.01 0.13-8.05 1.00 
Atlantic vs. Ontario and Northern 2.32 0.34-15.79 0.39 
    
Main Medical Reason   0.02 
Pain Relief vs. Mental Health 0.38 0.12-1.24 0.11 
Pain Relief vs. Central Nervous 
System 
0.20 0.03-1.26 0.09 
Pain Relief vs. Side Effects 3.41 0.50-23.43 0.21 
Pain Relief vs. Other 3.41 1.08-10.70 0.04 
Other vs. Mental Health 0.11 0.03-0.51 0.01 
Other vs. Central Nervous 
System 
0.06 0.01-0.49 0.01 
Other vs. Side Effects  1.00 0.13-7.81 0.10 
Mental Health vs. Central 
Nervous System 
0.51 0.06-4.04 0.52 
Mental Health vs. Side Effects 8.91 1.05-75.72 0.05 
Central Nervous System vs. Side 
Effects 
17.54 1.33-231.28 0.03 
    
Perception of smoking harm   <0.01 
Low vs. Middle 2.80 0.85-9.18 0.09 
Low vs. High 16.90 3.88-73.62 <0.01 
High vs. Middle 0.06 0.01-0.47 <0.01 
    
Respiratory Symptoms  0.62 0.46-0.86 <0.01 
    
Smoking Status   0.03 
Not at all vs. Occasionally  0.48 0.87-2.65 0.40 
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Not at all vs. Daily 0.16 0.04-0.64 0.01 
Daily vs. Occasionally  6.23 0.38-23.83 0.01 
    
The first category listed is the reference category for each. 
 
 
Table 14: Rating of Factors by Mode of Delivery (n= 342)* 
Factors Smoking Using a Vapourizer Eating in Food 
 Mean (SD) Mean (SD) Mean (SD) 
    
Time to onset of effect  4.1   (1.0)a 3.8   (1.1)a  2.1   (1.2)a 
Symptom relief 4.0   (0.9)a   3.9   (1.0)b  3.9   (1.2)c  
Accessibility 3.9   (1.2)a  3.6   (1.2)a  3.1   (1.4)a  
Type of “high”  3.8   (1.0)a 3.8   (1.0)b  3.6   (1.1)ab  
Ease of use 3.7   (1.2)a  3.8   (1.1)b  3.5   (1.4)b  
Ability to find correct dose 3.7   (1.2)a  3.7   (1.2)b  2.6   (1.3)ab  
Number of side effects 3.6   (1.2)a  4.0   (1.1)ab  3.7   (1.2)b  
Duration of effect  3.4   (0.9) a  3.3   (1.0) b 4.2   (1.0)ab  
Level of harm 3.3   (1.3)ab  4.2   (1.0)a  4.2   (1.1)b  
Amount needed for effect 3.1   (1.0)a  3.2   (1.2)b  2.4   (1.2)ab  
Cost 2.4   (1.2)ab  2.2   (1.2)a  2.2   (1.1)b  
Stigma 2.4   (1.3)a  2.9   (1.3)a  3.3   (1.3)a  
    
*Rating was completed on a scale from 1 to 5, where 1 represented the least desired effect and 5 represented 
the most desired effect.    
a,b,c Means with the same letter are significantly different at a p<0.05 tested using an ANOVA. 
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Table 15: Rating of Factors by Mode of Delivery ANOVA Output 
Factors  F-statistic P-value 
   
Time to onset of effect  273.33 <0.01 
Smoking vs. Using a Vapourizer  <0.01 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  <0.01 
   
Symptom relief 1.34 0.26 
Smoking vs. Using a Vapourizer  0.12 
Smoking vs. Eating in Food  0.18 
Using a Vapourizer vs. Eating in Food  0.85 
   
Accessibility 272.00 <0.01 
Smoking vs. Using a Vapourizer  <0.01 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  <0.01 
   
Type of “high”  7.01 <0.01 
Smoking vs. Using a Vapourizer  0.22 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  0.01 
   
Ease of use 2.76 0.06 
Smoking vs. Using a Vapourizer  0.94 
Smoking vs. Eating in Food  0.06 
Using a Vapourizer vs. Eating in Food  0.03 
   
Ability to find correct dose 75.97 <0.01 
Smoking vs. Using a Vapourizer  0.87 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  <0.01 
   
Number of side effects 19.39 <0.01 
Smoking vs. Using a Vapourizer  <0.01 
Smoking vs. Eating in Food  0.42 
Using a Vapourizer vs. Eating in Food  <0.01 
   
Duration of effect  79.90 <0.01 
Smoking vs. Using a Vapourizer  0.92 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  <0.01 
   
Level of harm 85.78 <0.01 
Smoking vs. Using a Vapourizer  <0.01 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  0.68 
   
Amount needed for effect 56.65 <0.01 
Smoking vs. Using a Vapourizer  0.13 
Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  <0.01 
   
Cost 270.00 0.01 
Smoking vs. Using a Vapourizer  0.01 
Smoking vs. Eating in Food  0.01 
Using a Vapourizer vs. Eating in Food  0.66 
   
Stigma 79.43 <0.01 
Smoking vs. Using a Vapourizer  <0.01 
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Smoking vs. Eating in Food  <0.01 
Using a Vapourizer vs. Eating in Food  <0.01 
   
 
 
Table 16: Main Form Logistic Regression Model Output (n=247) 
(C-statistic= 0.51) 
Covariates OR 95% CI P-value 
    
Gender  0.81 0.38-1.76 0.60 
    
Age  0.97 0.94-1.00 0.09 
    
Ethnicity  2.06 0.70-6.06 0.19 
    
Education   0.64 
Low vs. Moderate 1.54 0.63-3.77 0.35 
Low vs. High  1.28 0.43-3.87 0.66 
High vs. Moderate  1.20 0.46-3.16 0.71 
    
Income   0.58 
Low vs. Middle 1.51 0.54-4.20 0.44 
Low vs. High 1.72 0.53-5.59 0.37 
High vs. Middle 0.88 0.24-3.25 0.84 
    
Region   0.93 
Atlantic vs. Quebec 0.49 0.05-4.66 0.54 
Atlantic vs. Prairies  1.04 0.16-6.66 0.97 
Atlantic vs. British Columbia 1.20 0.20-7.42 0.84 
Atlantic vs. Ontario and Northern 1.05 0.20-5.40 0.95 
    
Main Medical Reason   0.70 
Pain Relief vs. Mental Health 2.42 0.73-8.06 0.15 
Pain Relief vs. Central Nervous 
System 
0.98 0.27-3.59 0.98 
Pain Relief vs. Side Effects 1.67 0.18-15.62 0.66 
Pain Relief vs. Other 1.14 0.37-3.51 0.83 
    
Perception of smoking harm   0.01 
Low vs. Middle 0.62 0.20-1.82 0.38 
Low vs. High 0.17 0.05-0.63 0.01 
High vs. Middle 3.58 1.38-9.29 0.01 
    
Respiratory Symptoms  0.83 0.66-1.04 0.10 
    
The first category listed is the reference category for each. 
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Table 17: Reasons for Using a Main Form Between Dried Herb and Alternative Forms Chi-Square Output 
Reasons X2 P-value 
   
Easy to use 1.00 0.32 
More accessible  18.55 <0.01 
Best symptom relief 0.71 0.40 
Easy to find dose 0.05 0.82 
Effects occur faster    1.93 0.17 
Uses less marijuana 1.78 0.18 
Effects last longer 24.39 <0.01 
More affordable 0.39 0.53 
Less side effects 10.04 <0.01 
Provides the best high 0.09 0.77 
Higher quality 5.04 0.03 
More potent 3.00 0.08 
Less harmful 34.67 <0.01 
Recommended to me 2.01 0.16 
Other 6.05 0.01 
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Table 18: Current Vapourizer Use Logistic Regression Model Output (n=250) 
(C-statistic=0.64) 
Covariates OR 95% CI P-value 
    
Gender  0.41 0.21-0.77 0.01 
    
Age  0.97 0.95-1.00 0.05 
    
Ethnicity  2.52 1.03-6.19 0.04 
    
Education   0.06 
Low vs. Moderate 1.38 0.68-2.79 0.38 
Low vs. High  3.16 1.20-8.34 0.02 
High vs. Moderate  0.44 0.19-1.02 0.06 
    
Income   0.35 
Low vs. Middle 0.68 0.30-1.51 0.34 
Low vs. High 1.47 0.55-3.97 0.45 
High vs. Middle 0.46 0.16-1.35 0.16 
    
Region   0.02 
Atlantic vs. Quebec 1.62 0.29-9.08 0.59 
Atlantic vs. Prairies  5.69 1.50-21.50 0.01 
Atlantic vs. British Columbia 2.58 0.72-9.23 0.14 
Atlantic vs. Ontario and Northern 5.29 1.73-16.19 <0.01 
    
Main Medical Reason   0.87 
Pain Relief vs. Mental Health 1.02 0.44-2.34 0.97 
Pain Relief vs. Central Nervous System 0.71 0.23-2.17 0.55 
Pain Relief vs. Side Effects 0.54 0.12-2.50 0.43 
Pain Relief vs. Other 0.76 0.31-1.84 0.54 
    
Perception of smoking harm   0.26 
Low vs. Middle 1.51 0.72-3.19 0.28 
Low vs. High 2.57 0.82-8.05 0.10 
High vs. Middle 0.59 0.22-1.59 0.30 
    
Respiratory Symptoms  0.78 0.64-0.95 0.01 
    
The first category listed is the reference category for each. 
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Table 19: Main Source for Obtaining Medical Marijuana Logistic Regression Model Output (n=246) 
(C-statistic=0.59) 
Covariates OR 95% CI P-value 
    
Gender  1.12 0.55-2.27 0.75 
    
Age  1.02 1.00-1.05 0.09 
    
Ethnicity  0.65 0.24-1.72 0.38 
    
Education   0.53 
Low vs. Moderate 0.69 0.31-1.54 0.36 
Low vs. High  0.59 0.21-1.60 0.30 
    
Income   0.58 
Low vs. Middle 0.74 0.30-1.79 0.50 
Low vs. High 1.37 0.46-4.04 0.57 
    
Region   0.09 
Atlantic vs. Quebec 0.41 0.05-3.48 0.41 
Atlantic vs. Prairies  0.60 0.09-3.78 0.59 
Atlantic vs. British Columbia 0.18 0.03-1.01 0.05 
Atlantic vs. Ontario and Northern 0.53 0.10-2.65 0.44 
    
Main Medical Reason   0.99 
Pain Relief vs. Mental Health 0.81 0.34-1.92 0.63 
Pain Relief vs. Central Nervous System 1.20 0.30-4.79 0.80 
Pain Relief vs. Side Effects 0.92 0.16-5.26 0.93 
Pain Relief vs. Other 0.92 0.35-2.43 0.87 
    
Perception of smoking harm   0.44 
Low vs. Middle 1.58 0.68-3.65 0.29 
Low vs. High 2.10 0.61-7.20 0.24 
    
Respiratory Symptoms  0.77 0.63-0.95 0.02 
    
The first category listed is the reference category for each. 
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Table 20: Ranking Comparison of Main Sources for Obtaining Medical Marijuana (N=364)† 
Factors Licensed Producer Grow it yourself Non-licensed 
Source 
 % (n) % (n) % (n) 
    
Cost    
Most Expensive (n=292) 64.7  (189) 7.5     (22) 27.7 (81)  
Least Expensive (n=261)  13.0    (34) 69.0  (180) 18.0 (47) 
Mean Rank (SD) 1.5    (0.7)a 2.6    (0.6)a 1.9  (0.7)a 
    
Time to receive    
Most amount of time (n=276) 32.6   (90) 57.2  (158) 10.1     (28) 
Least amount of time (n=261) 33.3   (87) 12.6    (33) 54.0  (141) 
Mean Rank (SD) 2.0   (0.8)a 1.5    (0.7)a 2.4     (0.7)a 
    
Accessibility    
Most accessible (n=301) 48.2  (145) 19.6     (59) 32.2    (97) 
Lest accessible (n= 261) 25.7    (67) 49.0  (128) 25.3    (66) 
Mean Rank (SD) 1.8    (0.8)a 2.3    (0.8)ab 1.9    (0.8)b 
    
Safety    
Highest standards (n=293) 72.4  (212) 21.2    (62) 6.5    (19) 
Lowest standards (n=255) 8.2    (21) 7.5    (19) 84.3  (215) 
Mean Rank (SD) 1.4   (0.6)a 1.9   (0.5)a 2.8    (0.6)a 
    
Quality     
Highest quality (n=275) 58.5  (161) 22.5   (62) 18.9    (52) 
Lowest quality (n=27)* 11.1      (3) 18.5     (5) 70.4    (19) 
Mean Rank (SD) ‡ ‡ ‡ 
    
Potency    
Most potent (n=265) 54.0  (143) 20.4   (54) 25.7    (68) 
Least potent (n=205) 28.8    (59) 25.4   (52) 45.9    (94) 
Mean Rank (SD) 1.8   (0.9)ab 2.0   (0.7)a 2.2    (0.8)b 
    
Symptom relief    
Best relief (n=274) 61.3  (168) 21.9   (60) 16.8    (46) 
Worst relief (n=187) 19.8    (37) 20.9   (39) 59.4  (111) 
Mean Rank (SD) 1.6    (0.8)a 1.9   (0.7)a 2.4    (0.8)a 
    
Stigma     
Most stigma (n=278) 3.6     (10) 27.3   (76) 69.1  (192) 
Least stigma (n=264) 87.5  (231) 8.0   (21) 4.5    (12) 
Mean Rank (SD) 2.8    (0.5)a 1.8   (0.6)a 1.4   (0.6)a 
    
†Ranking was completed, where 1 represents the factor ranked as most/high/best, 2 represents 
moderate/middle, and 3 represents the factor ranked least/low/worst (e.g., for the factor cost: 1=most 
expensive, 2=moderately expensive, and 3=least expensive).    
*Due to a programming error, only 27 participants answered this question. 
‡Ranking could not be done due to the small participant size.  
a,b,c Means with the same letter are significantly different at a p<0.05 tested using an ANOVA. 
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Table 21: Ranking Comparison of Main Sources for Obtaining Medical Marijuana ANOVA Output 
Factors  F-statistic P-value 
   
Cost                   131.64                 <0.01 
Licensed Producer vs. Grow it Yourself  <0.01 
Licensed Producer vs. Non-licensed Source  <0.01 
Grow it Yourself vs. Non-licensed Source  <0.01 
   
Time to receive 67.63 <0.01 
Licensed Producer vs. Grow it Yourself  <0.01 
Licensed Producer vs. Non-licensed Source  <0.01 
Grow it Yourself vs. Non-licensed Source  <0.01 
   
Accessibility 18.64 <0.01 
Licensed Producer vs. Grow it Yourself  <0.01 
Licensed Producer vs. Non-licensed Source  0.18 
Grow it Yourself vs. Non-licensed Source  <0.01 
   
Safety 253.00 <0.01 
Licensed Producer vs. Grow it Yourself  <0.01 
Licensed Producer vs. Non-licensed Source  <0.01 
Grow it Yourself vs. Non-licensed Source  <0.01 
   
Quality  - - 
   
Potency 9.19 <0.01 
Licensed Producer vs. Grow it Yourself  0.01 
Licensed Producer vs. Non-licensed Source  <0.01 
Grow it Yourself vs. Non-licensed Source  0.10 
   
Symptom relief  32.92 <0.01 
Licensed Producer vs. Grow it Yourself  <0.01 
Licensed Producer vs. Non-licensed Source  <0.01 
Grow it Yourself vs. Non-licensed Source  <0.01 
   
Stigma  352.95 <0.01 
Licensed Producer vs. Grow it Yourself  <0.01 
Licensed Producer vs. Non-licensed Source  <0.01 
Grow it Yourself vs. Non-licensed Source  <0.01 
   
 
